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ABSTRACT OF THE DISSERTATION 
DESIGN AND SYNTHESIS OF S-RIBOSYLHOMOCYSTEINE ANALOGUES 
by 
Christiane Chbib 
Florida International University, 2014 
Miami, Florida 
Professor Stanislaw Wnuk, Major Professor 
Bacteria are known to release a large variety of small molecules known as 
autoinducers (AI) which effect quorum sensing (QS) initiation. The interruption of QS 
effects bacterial communication, growth and virulence. 
Three novel classes of S-ribosylhomocysteine (SRH) analogues as potential inhibitors 
of S-ribosylhomocysteinase (LuxS enzyme) and AI-2 modulators of QS were developed. 
The synthesis of 2-deoxy-2-bromo-SRH analogues was attempted by coupling of the 
corresponding 2-bromo-2-deoxypentafuranosyl precursors with the homocysteinate 
anion. The displacement of the bromide from C2 rather than the expected substitution of 
the mesylate from C5 was observed. The synthesis of 4-C-alkyl/aryl-S-
ribosylhomocysteine analogues involved the following steps: (i) conversion of the D-
ribose to the ribitol-4-ulose; (ii) diastereoselective addition of various alkyl or aryl or 
vinyl Grignard reagents to 4-ketone intermediate; (iii) oxidation of the primary hydroxyl 
group at C1 followed by the intramolecular ring closure to the corresponding 4-C-
alkyl/aryl-substituted ribono-1,4-lactones; (iv) displacement of the activated 5-hydroxyl 
group with the protected homocysteinate. Treatment of the 4-C-alkyl/aryl-substituted 
SRH analogues with lithium triethylborohydride effected reduction of the ribonolactone 
vii 
 
to the ribose (hemiacetal) and subsequent global deprotection with trifluoroacetic acid 
provided 4-C-alkyl/aryl-SRHs. 
The 4-[thia]-SRH were prepared from the 1-deoxy-4-thioribose through the coupling 
of the α-fluoro thioethers (thioribosyl fluorides) with homocysteinate anion. The 4-[thia]-
SRH analogues showed concentration dependent effect on the growth on las (50% 
inhibitory effect at 200 µg/mL). The most active was 1-deoxy-4-[thia]-SRH analogue 
with sufur atom in the ring oxidized to sulfoxide decreasing las gene activity to 
approximately 35% without affecting rhl gene. Neither of the tested compounds had 
effect on bioluminescence nor on total growth of V. harveyi, but had however slight 
inhibition of the QS. 
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1.  INTRODUCTION 
1.1. Quorum sensing (QS) 
Bacteria are known to release a large variety of small molecules. They also produce 
and respond to diffusible signal molecules (termed autoinducers or pheromones). Cell to 
cell communication in bacteria is shown to be accomplished through the exchange of 
extracellular signaling molecules called autoinducers.1-4 This process is defined as QS 
where bacteria are allowed to coordinate gene expression. The concept of quorum 
sensing (QS) was discovered in the luminescent marine bacterium Vibrio fischeri.5 Light 
emission (the Luciferase enzyme) was only expressed when the organisms were 
associated with their fish or squid symbiotic hosts. The mechanism behind it was 
uncovered demonstrating that the expression of luciferase-encoding genes is related to a 
factor secreted by the cells and accumulates as cell density increases. Bioluminescence, a 
QS dependent behavior in Vibrio, was observed as a light production that was controlled 
by the secretion and the detection of small signal molecules.6-9  When a specific threshold 
is reached (Figure 1), programmed changes in gene expression coordinate population-
dependent behavior.5 Some of the changes that occur include biofilm formation, toxin 
and virulence secretion in addition to sporulation and swarming ability. QS was 
employed as a novel target for drug design especially in relation to pathogenic bacteria as 
Pseudomonas aeruginosa, Salmonella typhimutium, Yersinia enterocolitica and others.10 
Autoinducer (AI) molecules are molecule facilitators that are conventionally divided into 
two groups. Acyl homoserine lactones (AHL, AI-1),11 used in Gram negative bacteria 
and oligopeptides used in Gram positive bacteria (Figure 1). However the QS process is 
not limited to the previous two groups only, but include a universal group of autoinducer-
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2 (AI-2) found in both Gram positive and negative bacteria.12-16 It has been proposed that 
AI-2 represent a possible means by which different bacteria communicate with each other 
contrary to the intraspecies communication mediated by other autoinducers.12,17 
 
Figure 1. The signal molecules in quorum sensing process in Gram positive and 
negative bacteria.18 
QS was demonstrated to regulate many important traits including biofilm formation, 
virulence and gene transfer between bacteria.4,19 Understanding QS may simplify the 
means to inhibit or silence QS pathway and weaken bacterial pathogenicity. Most new 
antibiotics are the derivatives of older generations which present a universal threat when 
it comes to bacterial resistance. This leads to the necessity of the research for new 
antimicrobials with different mechanism of actions. Quorum sensing, is the process of 
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population dependent bacterial cell-cell signaling, which has a major impact on 
accelerating the bacterial virulence. It is considered an interesting target for new research 
in antibiotics. Antibacterials are divided into either bacteriostatic (inhibit bacterial 
growth) or bactericidals (cause bacterial cell death).17 The rise of a new family of 
antibacterial that belongs to neither but in fact operates by reducing selective pressure 
like quorum sensing mechanism has generated major interest.19 
The process of quorum sensing involves three major characters4 (Figure 2): (1) 
synthase, (2) signal, and (3) sensor. The synthase is the basic part of the model, since it 
initiates the process of quorum sensing by synthesizing small-molecule signals called 
autoinducers (AI) which when detected by the sensors at a threshold level generate gene 
expression. 
 
Figure 2. Quorum sensing model: Cell to cell communication.4 
QS signaling molecules (QSSM) or autoinducers are categorized into three major 
classes20,21 as illustrated in Table 1 and also shown in Figure 1. They are (a) N-
acylhomoserine lactone (AHLs) produced by Gram negative bacteria, (b) autoinducing 
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oligopepetide derivatives (AIP; see also Figure 6) employed by Gram positive bacteria, 
and (c) autoinducer-2 (AI-2) derived from the precursor 4,5-dihydroxy-2,3pentanedione 
(DPD) used by both Gram positive and negative bacteria (Figure 3). Other recognized 
QSSM consist of alkyl quinolones, for example, Pseudomonas Quinolone Signal (PQS or 
HHQ), autoinducer-322 and cholerae autoinducer 1 (CAI-1).23 
Pathway Signal molecule Bacteria 
AI-1 various AHLs Gram negative 
PQS and HHL Pseudomonas quinolone signal 
4-hydroxy-2-heptylquinoline  
Gram negative 
AI-3 Epinephrine/Norepinephrine Gram negative 
AI-2 Furanosyl borate esters of DPD Gram negative and positive 
AIP various oligopeptides Gram positive 
CAI-1 (S)-3-hydroxytricedan-4-one Gram negative (V. Cholerae) 
 
Table 1. Different Quorum sensing pathways in bacteria.17 
AHLs (1, Figure 3) vary in the length and the oxidation state of the acyl side chain.24 
Blackwell and co-workers21 found that the length of the acyl chain is critical for the 
activity of AHL. In the unique case of P.aeruginosa  a specific signal molecule having 
quinolone motifs such as PQS and HHQ is released from the cell.18 AI-2, a furanosyl 
borate ester of DPD in V. harveyi 2, exists as non-borated in S. typhinium 2a (Figure 3).                            
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Figure 3. Chemical structures of QS signaling molecules (QSSM).24 
1.1.1. Intraspecies quorum sensing  
In Gram positive bacteria, signaling pheronomones are generally peptides.  They  
signal through receptor-histidine kinases (RHKs) that are embedded in the membrane.25 
The intraspecies communication in Gram-positive bacteria is through autoinducing 
peptides (AIP)17 in the form of oligopeptides consisting of 5-20 residues, whereas in 
Gram negative bacteria, acetylated homoserine lactones (AHL) are used as autoinducers 
which consist of small molecules diffusible across the cytoplasmic membrane and able to 
bind to the regulatory proteins within the cell to trigger transcriptional changes.12,25  
In Figure 4 part A, peptide signaling through receptor-histidine kinases (RHKs) in 
Gram positive bacteria shows that the extracellular signaling molecules bind to the sensor 
domain of the RHK leading to the activation via phosphorylation and dephosphorylation 
of the HK domain. Then gene expression is controlled at the level of transcription. In 
Gram negative bacteria (Figure 4 part B), small signaling molecules cross to the 
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intracellular receptor protein R. Upon binding, R is stabilized in a form that binds to 
DNA leading to the modulation of gene expression. 
 
Figure 4. The different signaling in Gram positive (A) and negative bacteria (B).25 
1.1.1.1. Gram positive bacteria 
Intraspecies communication in Gram positive bacteria as S. aureus, is related to the 
secretion of an extracellular peptide AIP and to its accumulation.25 Upon reaching a 
threshold, AIP binds to the sensor protein (histidine kinase protein H, HKPH) located in 
the cell membrane of the bacteria and triggers the activation of the receptor-histidine 
kinase AgrC. HKPH is part of a two-component signal transduction system. The QS 
system includes the sensing protein (receptor) and a response-regulatory protein which 
controls gene activation and positive feedback regulation of AIP (Figure 5). Kinase 
protein H is activated when binding to AIP, leading to its autophosphorylation. The 
phosphoryl group is transferred to an aspartate residue D that undergoes subsequent 
phosphorylation leading to the activation of the response regulatory protein (peptide-
pheromone precursors). The latter is cleaved to afford the autoinducer signal exported by 
7 
 
the ATP-binding cassette (ABC)26. Once exported, AIP can be sensed by self and other 
bacteria.  
 
Figure 5. QS mediated by peptides pheromones and two-component regulatory 
systems in Gram-positive bacteria.26 
The autoinducing peptides AIP are the short oligopeptide fragments17 that are post-
translationally modified through the insertion of a lactone, thiolactone, lanthionine or 
isoprenyl group to yield diverse structures (Figure 6). They could differ in binding 
selectivities and activation in different Gram positive bacteria.   
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Figure 6. Structures of the selected AIPs.17 
1.1.1.2. Gram negative bacteria 
The mechanism of QS in Gram negative bacteria starts with the secretion of 
autoinducers or pheromones (AHL). When the inducer binds to the receptor, it activates 
the transcription of certain genes. As the population of bacteria grows a positive feedback 
is started.27 The AHL molecules are composed of fatty acyl chain linked to a lactonised 
homoserine through an amide bond.28 Different structures of AHLs which modulate 
different regulatory proteins in different bacteria are presented in Table 2. They are the 
subject of vast literature reports.17,29-41 Their structure and composition vary in the acyl 
chain and lead to different biochemical and physiological functions.17  
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Organism Signal Regulatory proteins Phenotype 
A.hydrophila C4-HSL Ahy1/AhyR Exoprotease 
production 
A.salmonicida C4-HSL AsaI/AsaR Extracellular 
protease 
A.tumedaciens 3-oxo-C8-HSL TraI/TraR Ti plasmid 
conjugation 
B.cepacia C8-HSL CepI/CepR Protease 
siderophores 
C.violaceum C6-HSL CviI/CviR Exoenzyme, 
antibiotics 
E.carotovora C6-HSL ExpI/ExpR Exoenzyme, 
carbapenem 
antibiotic 
E. chrysanthemi 3-oxo-C6-HSL ExpI/ExpR Pectate lyase 
P. aureofaciens C6-HSL PhzI/PhzR Phenazine antibiotics
P. aeroginosa 3-oxo-C12-HSL LasI/LasR 
RhII/RhIr 
Multiple 
extracellular 
enzyme, biofilm 
formation 
R.sphaeroides C14-HSL CerI/RhIR Dispersal from 
bacterial aggregate 
S.liquefaciens C4-HSL SwrI/SwrR Extracellular 
protease 
V.fischeri C6-HSL LuxI/LuxR Bioluminescence 
V.harveyi 3-hydroxy-C4-HSL LuxM/N Bioluminescence 
Y. 
pseudoruberculosis 
C6-HSL YpsR/I 
YthR/I 
Regulation of 
clumping and 
motility 
Y. pestis C10-HSL/C6-HSL 
 
YspI/YspR 
YpeI/YspR 
Regulation of 
clumping and 
motility 
 
Table 2. Representative AHLs and their function in Gram negative bacteria.17,29-41 
The N-acyl-L-homoserine lactones (1, AHLs) are derived from S-adenosylmethionine 
(SAM, 3, Scheme 1) with the assistance of the enzymatic action of LuxI25,42 as shown in 
Scheme 1. Intramolecular cyclization of the homocysteine fragment with the elimination 
of the 5'-S-methyl-5'-thioadenosine and the concomitant acylation of the amino group 
with the common acyl carriers provided various AHL analogues.   
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Scheme 1. Biosynthesis of N-(acyl)-L-homoserine lactone.25  
The mechanism of action of AHL QS starts with the diffusion of the latter in the cell 
(Figure 7).  The interaction with the LuxR-type protein leads to acyl-HSL bond 
formation. It is divided into two domains: first, the conserved one which includes the N-
terminal of LuxR from acyl-HSL-binding region; second, the C-terminus with a helix-
turn-helix motif (HTH) required for DNA binding. The binding between N-terminal and 
acyl-HSL leads to conformation changes followed by a DNA binding.17   
 
Figure 7. AHL quorum sensing mechanism.17 
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E. coli and S. typhimurium are common causes of food-bourne illness.43 They are 
believed to have homologous QS pathways.44 In solution, DPD undergoes rapid 
cyclisation (see below Scheme 4) and exists in equilibrium with several different 
isoforms. Thus AI-2 is not a specific molecular structure but a family of isomers.45 The 
recruitment of boron is needed for the case of V. harveyi.18 As shown in Figure 8a below, 
the AI-2 QS process in both E. coli and S. typhimurium is regulated by the same LuxS-
regulated operon (lsr). After DPD cyclizes to form AI-2, it gets exported extracellularly 
where it accumulates. Once a threshold is reached, the bacterial QS is initiated and signal 
transduction is activated. AI-2 is imported by lsr inside the cell, via lsr transporter,46 
where it gets phosphorylated by kinase to form phospho-AI-2. This form allows it to bind 
to LsrR known as a repressor which effects it to be released. A positive feedback is used 
causing increased expression of the transporter and resulting in more importation of AI-2.  
In case of V. harveyi and V. cholerae 47 (Figure 8b), the three cognate receptors CqsS 
(mediated by CAI-1),48 LuxN (mediated by AI-1) and LuxQ (which interacts with the 
complex LuxP-AI-2) are membrane-bound histidine sensor kinases.49 The sensory 
mechanism is a two-component regulatory path that produces LuxR.50-53 The role of 
LuxR is to control the expression of bioluminescence related genes. At low 
concentrations, the cognate receptors act as kinases and lead to the formation of 
phosphor-LuxO and then the synthesis of sRNA that leads to the degradation of luxR 
mRNA. At high concentrations, the cognates switch from kinases to phosphorylases and 
remove phosphate from LuxO to LuxU which permits translation of luxR mRNA to 
LuxR and expression of bioluminescence.4  
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Figure 8. Quorum sensing pathways in E. coli and S. typhimurium and V. harveyi.18 
An important example of Gram negative bacteria is Pseudomonas aeroginosa, capable 
of infecting insects, plants, animals and humans. As an opportunistic pathogen, it 
colonizes immunocompromised hosts.54,55 It is most prominent in patients with cystic 
fibrosis (a common lethal, genetic disease where the patient often dies because of 
impaired lung function). A key factor that contributes to the pathogenesis of P. 
aeroginosa and antibiotic resistance is its ability to form a biofilm that attaches either to 
an interface or to each other, inhabit an extracellular polymeric matrix and exhibit a 
phenotype distinct from the planktonic cells in terms of gene expression, growth and 
protein production.56 
P. aeruginosa is unique from the other pathogens described here since it does not 
make its own AI-2.16 P. aeruginosa utilizes two LuxI/R systems: LasI/R and RhII/R, 
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which work in coordination to control the expression of various QS associated virulence 
factors57 (Figure 9).  Both LasI and RhII produce different AHL autoinducers, N-(3-
oxododecanoyl)-HSL (OdDHL) and N-butyryl-HSL (BHL), respectively.58 Once 
activated by OdDHL, LasR boosts the expression of the rhl regulon through mvfR, which 
causes a subsequent increase in 4-hydroxy-2-heptylquinoline (HHQ, Figure 3) 
and Pseudomomas quinoline signal (PQS, Figure 3) production. The PQS signal is 
released through the extracellular membrane due to its hydrophobic properties, whereas 
HHQ stays intracellular. By regulating rhl and mvfR, LasR controls the production of the 
virulence factors and biofilm formation.59  P. aeruginosa QS is capable of sensing both 
AHL signaling and AI-2.16  
 
Figure 9. Quorum sensing circuit in P. aeruginosa.18 
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1.1.2. Interspecies quorum sensing  
1.1.2.1. S-Ribosylhomocysteinase (LuxS): Structure and functions 
LuxS is a small metalloenzyme containing Fe2+ ion tetrahedrally coordinated by His-
54 and His-58, Cys-126 and a water molecule. A highly conserved Cys-84 is located 4.86 
Å from the metal ion. It is widely preserved among Gram negative and Gram positive 
bacteria.60-64 The structure determination of LuxS protein revealed an α and β fold64 
featuring a four-stranded β-sheet partially surrounded by five helices. The β-sheet is 
composed of sheets 1, 2, 4, 3 and a 310 helix. Helix α1 is adjacent to β1 and β3. Helices 
α2, 3 and 4 are perpendicular to α1 (Figure 10A). Crystal structure of the protein revealed 
that LuxS is a homodimer with the subunits related by crystallographic symmetry. The 
central part is a dimeric interface that consists of β-sheets coming from each monomer.64 
The dimeric interface has an extensive surface burying 2,125 Å2 of solvent-accessible 
area per monomer compared to 1,685 Å2 as a mean surface for other dimers.65   In Figure 
10B, the letters A and B designate the two chains of the dimer of LuxS.        
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Crystal structure  
     
 
Figure 10. (A) Crystal structure of LuxS64; (B) A stereoview of the active site of 
LuxS.66   
LuxS mechanism of catalysis 
The formation of AI-2 (2) starts with S-adenosyl-L-homocysteine (3a, SAH, Scheme 
2) which is a product of S-adenosyl L-methionine (3, SAM)-dependent methylation. The 
hydrolysis of SAH by 5'-methylthioadenosine nucleosidase (MTAN) leads to adenine 
molecule and S-ribosyl-L-homocysteine (4, SRH). Afterwards, The SRH is cleaved by 
LuxS enzyme into L-homocysteine (Hcy) and 4,5-dihydroxy-2,3-pentanedione (DPD) 
which is the precursor of AI-21 (2, Scheme 2). The formation of AI-2 molecule is the 
result of a straightforward path that involves DPD (5) and boronic acid. The cyclization 
of DPD was shown to be thermodynamically favorable leading to the tetrahydrofuranone 
derivative pro-AI-2 (see also Scheme 5) that will complex with boronic acid to form the 
cyclic borate diester (AI-2). 
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Scheme 2. Pathway for the conversion of SAM to AI.18  
Pei and coworkers in 2003 proposed the pathway for the catalytic mechanism of S-
ribosylhomocysteine 61,67 presented in Scheme 3. Based on the kinetic, spectroscopic and 
labeling experiments they proposed that in the first initial step, coordination between the 
metal in LuxS and a water molecule occurs, making the newly formed open sugar 
complex 6 act as a Lewis acid. The acidic proton at C2 position in SRH complex 6 is then 
abstracted by the basic Cys-84 present at the β-face of the SRH substrate at the active site 
of LuxS. The formed enediolate 7 undergoes ligand exchange with the C2-OH group 
assisted by a Glu57. Tautomerisation to keto form generates a carbonyl at C2 position 
(8). The repetition of this enolization-tautomerization step leads to the formation of the 3-
keto SRH complex (9), which is prone to a β-elimination (10 → 11) of homocysteine 
catalyzed by Glu57. The release of the homocysteine as a free thiol molecule occurs 
17 
 
simultaneously with the formation of DPD in its enol form which will immediately 
tautomerize into the more stable keto form (5). DPD will then undergo cyclization to 
form a tetrahydrofuranone derivative (5a) which upon further complexation with boronic 
acid will lead to the formation of borate complex AI-2. Therefore, LuxS enzyme catalysis 
can be divided into three main steps: First the migration of carbonyl group from C1 to C2 
position, then the shift of the carbonyl to C3 position and finally the β-elimination Hcy 
and formation of DPD. 
 
Scheme 3. Proposed mechanism of LuxS- catalyzed reaction.60,61 
1.1.2.2. The signaling pathway of autoinducer-2 (AI-2)  
Structure of AI-2. 
AI-2 (2) is the universal signal molecule68-70 generated by LuxS synthase enzyme. 
Due to the fact that the differentiation in AI-2 signaling occurs at the transduction level, 
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different bacteria respond to AI-2 differently. The structure of AI-2 contains two fused 
five-membered rings located within the LuxP binding site. The hydrogen binding 
network is the main cause that stabilizes AI-2 molecule in the binding site (Figure 11). 
AI-2 interacts with different amino acids, the two arginines 215 and 310 present in the 
active site which are the positively charged residues that form hydrogen bonding with 
three borate oxygens in AI-2 and therefore stabilize the negative charge of the borate.   
 
Figure 11. Interaction of the furanosyl borate diester (AI-2) with the amino acids at 
the binding site.1 
AI-2: A common language among bacteria: 
Unlike other autoinducers, AI-2 does not resemble any other signaling molecules.42 It 
is proposed to serve as a universal signal for inter-species communication (Figure 12). It 
includes a group of signal molecules formed from a common precursor 4,5-dihydroxy-
2,3-pentanedione (DPD) (5 ; Scheme 2). In its turn, DPD is a bacterial by-product of the 
activated methyl cycle in a reaction catalyzed by LuxS.71 In a co-culture, the E. coli 
produces AI-2, which is sensed by S. typhimurium. 
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Figure 12. Bacterial cross-talk through AI-242 
The crystal structure of AI-2 (Figure 13) in complex with its required signaling partner, 
LuxP, was revealed by Bassler and coworkers72 containing the furanosyl borate diester.   
 
Figure 13. A schematic illustration of AI-2 with LuxP.1 
To date, two classes of AI-2 specific receptors have been identified: LuxP family 
found in vibrio sp. and the LsrB family identified in S. Typhimurium.3 Miller et al. 73 
identified a non-borated enantiomer of DPD (2R,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran-borate, R-THMF, Scheme 4) ligand in a crystal structure of 
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an AI-2 receptor LsrB from the Salmonella enterica species. These studies demonstrated 
that bacteria have the ability to detect different molecules based on the stereochemical 
assignment including differentiation of enantiomers.   
Formation of DPD:  
AI-2 is a collective name for a group of signaling molecules formed from 4,5-
dihydroxy-2,3-pentanedione (DPD, 5).44,71,74-76 DPD is an enigmatic molecule that has 
been known since 1971 as a bacterial byproduct45 of the activated methyl cycle in a 
reaction catalyzed by LuxS.71 DPD is the product of the cleavage of S-
ribosylhomocysteine (SRH) (Scheme 3) which spontaneously cyclizes into furanone 
derivatives (Scheme 4):  (2S,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran-borate (S-
THMF-borate) and (2R,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran-borate (R-
THMF) which are known by specific periplasmic binding proteins in V. harveyi and S. 
enterica respectively.1,73 DPD can be also synthesized from ribulose-5-phosphate and 
although this pathway is not clinically significant it has been proved to be an important 
metabolic passageway for DPD.77,78 DPD has recently been synthesized45,79 by 
Semmelhack and Meijler and their coworkers. It exists in an equilibrium mixture of two 
cyclic tetrahydrofuranone isomers: S-DHMF ((2S,4S)-2-methyl-2,4-
dihydroxytetrahydrofuranone) and R-DHMF ((2R,4S)-2-methyl-2,4-
dihydroxytetrahydrofuranone) (Scheme 4) with the respective hydrated analogues S-
THMF and R-THMF. When complexed to boronic acid, only the S-DHMF forms S-
THMF-borate known as AI-21 (2, Scheme 2).  
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Scheme 4. Biosynthetic pathways for the formation of DPD and AI-2.3 
DPD undergoes spontaneously cyclization to the corresponding tetrahydrofuranose 
derivative known as pro-AI-2. Hydration reactions in solution produced R-THMF 
diastereoisomers. In the presence of Boronic acid, the S-THMF undergoes complexation 
to form S-THMF-borate known as AI-2 (Scheme 5).  
 
Scheme 5. Cyclization pathway of DPD to AI-2.80 
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1.1.3. Strategies for quorum quenching (QQ) 
 The disturbance of quorum sensing should reduce pathogenicity.5,81 The approach 
of interfering with or destroying the QS signal is referred to as Quorum quenching (QQ). 
Strategies for quorum quenching include competing with the native signaling process 
either by creating signal molecules analogs, limiting signal generation or destroying the 
native molecules by sequestering traps. Organization of the quorum quenching is based 
on the location of the quenching in the track. It could either occur at the signal generator, 
the signal itself or the signal receptor and transducer (Figure 14). Currently there are 
three models being followed for the development of QQ agents. First, inhibition of 
QSSM synthase, for example LuxS in case of AI-2 QS82-84 or LuxI type in case of AHL-
based systems.85 Second, neutralization of QSSM by protein based strategies as QSSM 
degrading enzyme86 or sequestrating antibodies.87-89 Third, imitation of the ligand at the 
receptor level through QSSM analogs.56,90-92 Other strategies have been employed 
including inhibition of the signal secretion93,94 or interference with the downstream 
signal.95   
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Figure 14. Strategies for quorum quenching.18 
The QS mechanism in E. coli consists of various luxS regulated lsr genes.46 Signal 
transduction by lsr gene expression, characterizes the native AI-2 QS response (Figure 
15a). By binding to the transcriptional repressor LsrR, phospho-AI-2 induces 
transcription of the lsr genes. Roy and coworkers,42 tried to quench the cross 
communication among different bacteria (Figure 15b) using LsrK, an enzyme that 
phosphorylates AI-2 upon uptake into the cell, using ATP. LsrK and ATP are delivered 
outside the cell and phosphorylation of AI-2 leads to the unstable phosphor-AI-2 that 
auto-degrades to 2-phosphoglycolic acid (PG) overnight, which is then prevented from 
being carried into the cells. They demonstrated that when LsrK and ATP where added ex-
vivo to bacteria, the native QS response significantly diminished. 
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Figure 15. Schematic LsrK-mediated quenching.42 
1.2. Dimerisation inhibition 
LuxS enzyme is a metalloenzyme with a symmetrical dimer structure that catalyzes 
the non-redox cleavage of the stable thioether bond in SAM cycle with no need of NADH 
cofactor for the chemical reaction.60 Introducing a dimer inhibitor molecule to LuxS 
might be considered as a new strategy for the inhibition of the LuxS enzyme which has 
not been studied before. Some other dimer inhibitors that have been designed in 
litterature act on different dimer enzymes. Examples of dimer inhibitors include 
Herceptin® 96 (Trastuzumab) and TSAO-T.97 
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1.2.1. Examples of dimer inhibitors of other enzymes  
Since many enzymes are homodimers or multimers, the disturbance of the 
stereochemical orientation between protein subunits offers another rational way for 
enzyme inhibition leading the ability to alter the function of the enzyme.65 One important 
example would be Trastuzumab, a new anticancer agent (monoclonal antibody) that binds 
to the juxtamembrane region of the human epidermal growth factor receptor 2 known as 
HER 2. Trastuzumab deactivates the kinase, providing a steric barrier to the interaction of 
the transmembrane region and consequently disrupts HER 2 interactions with the 
protein.96 Also, a thymidine nucleoside analogue modified at the C3 position with a spiro 
sulfonate ring belonging to TSAO family (12, Figure 16), which is a part of the non-
nucleoside reverse-transcriptase inhibitors known as NNRTI, is used as a selective 
inhibitor against HIV-1 virus, by binding to the p66/p51 dimer subunit interface.98  
 
Figure 16. TSAO-T, selective inhibitor of HIV-1.99 
1.2.2. Dimerization process in LuxS enzyme  
LuxS enzyme is a small (35 kDa) homodimeric protein.100 In theory, SRH is 
positioned in between the two monomers at the active site of LuxS. The stereoview of the 
atomic interactions between LuxS and the 2-ketone intermediate reveals that the subunit 
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A of the dimer has the metal ion of the active site (in gold color in Figure 17), whereas 
the subunit B atoms shown in cyan color,101 hold the catalytic residue Cys84 and 
contribute less to the substrate binding residues (Notice that the oxygen atom of the 2-
ketone position of the intermediate is coordinated to the cobalt ion. Also the Ala-84 of the 
Cys-84-ala LuxS protein is positioned near the C2 and C3 atoms). Thus, the insertion of a 
dimer inhibitor in between the two monomers would theoretically prevent their 
interactions. The lack of coordination between subunits A and B should lead to the 
inactivation of the LuxS enzyme, since the catalytic role of subunit B which includes the 
cleavage of SRH to DPD would not be associated with subunit A due to the steric 
insertion between the two subunits.101 
 
Figure 17. LuxS dimer active site.101 
Studies have been conducted to explain the constituent of the interface of LuxS. They 
aim to show the mechanism of ligand binding and chain connectivity in protein 
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dihydrofolate reductase (DHFR). The dimeric state of LuxS enzyme of four organisms 
which were available to study demonstrated a distinctive fold to the alpha-beta family of 
proteins.102 The LuxS interface includes three vertices of an isosceles triangle. Two of the 
active clusters have the active site residue while the third one, apex cluster, located at the 
apex of the dimer with the display loop residues in a mini-triad form arrangement. The 
active site clusters are made up of three histidines and one glutamine from one subunit 
and a phenylalanine residue from the other subunit. Thus the active site of subunit A is 
supported from phenylalanine of subunit B and vice versa.102 This triad is repetitive 
between the two subunits of the dimeric protein. The mutation of any of the components 
of the triad has been showed to inactivate LuxS enzyme.102  
 
Figure 18. Schematic representation of isoceles orientation of the LuxS.102 
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Recently SRH analogues modified at the homocysteine unit (4a) were proposed as 
potential dimer inhibitors of LuxS (Figure 19).103,104 It was hypothesized that inhibitors 
with the inserted long alkyl/aryl chain at either the β-carbon or the γ-carbon of Hcy unit 
should interfere with two monomers of the protein, which might alter the proximity 
between the monomers, which in turn should lead to a change in enzyme activity. The 
steric hindrance at the dimerization site caused by 4a would result in dimer disruption 
and subsequently a change in the proximity of the LuxS monomers. It was also proposed 
that fluorescence proximity assay might be used for the detection of the dimerization 
inhibition of LuxS by measuring the change in fluorescence upon monomer separation105-
107 resulting from the supposed interaction of inhibitors 4a with LuxS protein. 
 
Figure 19. SRH analogues proposed as potential dimerization inhbitors.103,104 
1.3. Inhibition of LuxS enzyme by substrate analogues 
General approaches towards the modulations of QS, and AI-2 inhibition strategies in 
particular, are presented in Table 3. As can be concluded based on the biosynthetic 
pathway for the production of DPD and consequently AI-2 presented in Scheme 3, the 
major target responsible for QS inhibition is the LuxS enzyme which controls the 
production of AI-2.   
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Inhibitor 
Target 
Active site Inhibitors 
Signal 
generators 
SAH/MTA 
nucleosidase 
(Pfs) 
                     
 
4-CPS derivative                               Dansyl derivative 
Ki = 4 µM108                                       Ki = 1 µM108 
 
LuxS enzyme Competitive substrate inhibitors and SRH analogues 
Signal 
molecules 
AI-2 Introducing LsK and ATP to phosphorylate AI-242 and 
prevent its intracellular uptake 
Signal 
receptor/ 
transduction 
DPD 
analogues109 
 
Various Brominated 
furanones110-112 
 
 
Table 3. Overview of QS inhibition strategies18,42,60,84,109,113-119 
1.3.1  S-ribosylhomocysteine substrate analogues 
Absent in humans, the LuxS enzyme is considered a smart target for novel 
antibacterials. Zhou and coworkers19 were the first to develop synthetic analogues of 
SRH which act by competing with the natural substrate SRH 4 (Figure 20). The first 
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competitive substrate analogue was S-anhydroribosyl-L-homocysteine 13a19 in which the 
hemiacetal group has been replaced by an ether functional group. Compound 13a should 
prevent the first step in the catalysis of LuxS enzyme known as the aldo-ketose 
isomerization.83 The presence of the 2,3-diol functional group was expected to ligate to 
the active site metal ion which allows it to bind to LuxS in a similar fashion as SRH. The 
second substrate analogue S-homoribosyl-L-cysteine 13b19 had a replacement of the 
carbon–sulfur bond (C5-Sulfur) in SRH 3 by a carbon-carbon bond (C5 and C6). 
Substituting the sulfur atom by a carbon at position 6 should allow 13b to bind properly 
to LuxS enzyme and undergo aldo-ketose isomerization to form a ketone at C3 of 13b. 
Further elimination reaction would however be prohibited since the cleavage of the 
carbon–sulfur bond cannot occur, preventing elimination of Hcy.   
 
Figure 20. Substrate inhibitors of LuxS enzyme designed by Zhou and coworkers.19 
Pei and coworkers60 designed and synthesized substrates for LuxS enzyme with the 
an open ribonic acid moiety (Figure 21). Thus, the replacement of the enediolate moiety 
with a planar hydroxamate group in compound 14120,121 was envisioned to produce                      
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a stable isostere with high affinity to LuxS. The metal ion in LuxS which was proposed to 
give the stability of the enediolate intermediate e.g. (4, Scheme 2) was expected to bind 
to the planar hydroxamate group in 14. As a stereoisomer of 14 at the β-carbon of the 
hydroxamate, compound  15122 was expected to have similar LuxS inhibition. Compound 
16 (without a Hcy moiety) was also tested to check the importance of the Hcy moiety in 
the proper binding of the inhibitor to the active site of LuxS. Pei etal. also proposed 
compound 17 in which the amino acid portion and a metal chelating group (N-
formylhydroxylamine) are linked.  These compounds were tested against co-(II)-
substituted B.subtilis LuxS, compounds 14 and 15 acted as potent competitive inhibitors 
with respective Ki = 0.72 and 0.37 µM. Compound  16 had a lower affinity of  Ki > 150 
µM which reinforced the importance of the amino acid moiety in the affinity to LuxS. 
Compound 17 exhibited slight inhibition with Ki = 68 µM whereas the SRH analogues 18 
and 19 having Hcy amino acid unit modified did not show inhibitory activity. 
 
Figure 21. Substrate inhibitors of LuxS enzyme designed by Pei and coworkers60 
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Wnuk and coworkers investigated two groups of potential LuxS inhibitors.123,124 One 
group had a vinyl or halovinyl moiety incorporated at C5 of SRH as depicted in 
compounds 20-23 (Figure 22). In compounds 20-22, the incorporation of the fluoro-vinyl 
unit was envisioned to target the final step in the LuxS mechanism preventing the β-
elimination to occur. These compounds tested also a possible hydrolytic activity of LuxS 
enzyme since it was shown that a related S-adenosylhomocysteine hydrolase which also 
catalyzes C5-sulfur bond in the S-adenosylhomocysteine, was able to add water across 
the isolated C5'-C6' bond.123,124 As for 23,123 the lack of the hydroxyl group at C3 of the 
sugar should prevent the second enolization step of the LuxS catalyzed reaction. No 
significant inhibition has been reported for the above compounds except 23 (Table 4).                         
The second group of SRH analogues had carbon-3 modification in the ribose ring. These 
compounds should prevent the second enolisation step in the LuxS catalysis because of 
(i) the lack of the hydroxyl group as in 3-deoxy-analogue 24, (ii) the lack of the 
enolizable proton in 3-methoxy analogues 25 and 26, (iii) the inversion of the 
stereochemistry at C3 as in xylo-analogue 27, or (iv) the replacement of the 3-hydroxyl 
group by a halogen atom as in 28 and 29 (Figure 22). Compounds 28 and 29 showed 
time-dependent inhibition of LuxS, while compounds 20-22 did not show any inhibitory 
activity. The loss of fluoride ion via the postulated E1cB elimination reaction in 28 
instead of the nucleophilic substitution in the bromo atom in 29 led to the faster 
conversion of the initial enzyme-inhibitor complex E·I in 28 into a tighter enzyme-
inhibitor complex E·I* than in 29. 
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Competitive 
inhibitors 
Compound Ki 
23 96 µM 
24 55 µM 
25 66 µM 
26 42 µM 
28 10.6 µM 
29 7.9 µM 
 
Table 4. Ki values of different substrate inhibitors of LuxS.124,125 
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Figure 22. Substrates of LuxS enzyme synthesized by Wnuk and coworkers.123,124 
Two 3-halogeno-substituted SRH analogues (3-Br-SRH; 29 and 3-F-SRH; 28) acted 
as potential suicide inhibitors for LuxS.125 Since both molecules have a halogen (either 
bromide or fluoride) at carbon C3 instead of a hydroxyl group, they were expected to  
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bind to the active site of LuxS and to alert the enolization reaction that occurs at C3 to 
prevent the ketone formation at C3 (see Scheme 3). Detailed mechanistic studies 
performed in Professor Pei's laboratory demonstrated that 3-[Br]-SRH 29 and 3-[F]-SRH 
28 inhibit LuxS by different mechanisms.125 In the case of 29, the negatively charged 
Cys-84 nucleophilically attacks C3 in 29b (reactive α-bromoketone) leading to the loss of 
bromide ion and the formation of a new covalent adduct between C3 of the ribose ring 
and the sulfur atom of Cys-84 as shown in 29c (Scheme 6).     
 
Scheme 6. Proposed mechanism for the inhibition of LuxS by 3-Br-SRH.125 
In the case of 28, the negatively charged Cys-84 abstracts the acidic α proton at C2 of 
the hydroxy-aldehyde 28a leading to the loss of fluoride ion via the postulated E1cB 
elimination reaction. The formed enol 28b could exist in equilibrium with the diketone 
28c or undergo hydration to form 28d (Scheme 7).       
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Scheme 7. A plausible mechanism for the inhibition of LuxS by 3-F-SRH.125 
Wnuk and coworkers also designed the 4-aza-SRH analogues, in which nitrogen 
replaces the oxygen atom of the furanose ring (Figure 23).126 The hemiaminal derivatives 
(e.g. 32) were expected to have different stabilities compared to the O,O-hemiacetals 
present in SRH 3 which should result in different rates of metabolism. The binding 
strength of the aza analogues were expected to be different than the hemiacetals mainly 
because of the higher basicity of the nitrogen atom in the aza compounds as compared to 
the oxygen atom in the natural substrate SRH. Thus the binding strengths and rate of 
production of the open chain aldehyde was expected to be different. In addition, the 
aminosugars are more prone of protonation at physiological pH which should also alter 
the enzymatic activity. 
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Figure 23. 4-[aza]-SRH analogues.126,127 
The aza-analogue 30 lacking a hydroxyl group at C1 showed a concentration –
dependent inhibition of LuxS that was consistent with competitive inhibition (Ki = 48 
µM). The lactam 31b had a Ki value of 37 µM while the N-benzyl protected lactam 31a 
was found to be inactive mostly due to the steric reasons. The aza analogues lacking 
hydroxyl groups at C2 and C3 as in 33-35 were inactive mainly due to the absence of the 
hydroxyl groups which are important to coordinate with the catalytic metal ion in the 
LuxS protein. Unlike other aza-analogues, the hemiaminal 32 was found to be a time-
dependant inhibitor of LuxS with IC50 value of 60 µM and Ki value of 3.5 µM. The time-
dependent inhibition of LuxS by 32 might indicate that the hemiaminal exists in the 
equilibrium with the free aldehyde form 32a as depicted in Figure 23. The aldehyde 32a 
was proposed to undergo aldose-ketose isomerization reaction to generate 2-keto 
intermediate 32b and consequently 3-keto intermediate 32c. However, no spectroscopic 
proofs for the presence of the formation of the 2 or 3-keto intermediate were found.126 
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The mechanism of inhibition of LuxS by aza-analogues appears to be similar to the initial 
step of the inhibition of LuxS by the halogenated SRH analogues such as [3Br-SRH] and 
[3-F-SRH] which also showed to undergo LuxS-catalysed ring opening.125  
 
Scheme 8. Plausible mechanism for the time-dependent inhibition of LuxS by 4-aza-
SRH hemiaminal 32.126 
The aza analogues 33 (aza-hemiacetal) and the corresponding lactam 34 in which the 
Hcy unit was replaced by an alkyl-thio group bearing a long alkyl chain, acted as strong 
inhibitors against AHL-dependent las (activity 43% at [1.16 mM] inhibitor 
concentration) and weaker ones against rhl (activity 104% at [1.16 mM] inhibitor 
concentration) QS pathways in P. aeruginosa. Antagonism of las activity has been 
increased with the length of the alkyl-thio chain. The hexylthio-analogue 33b appeared to 
be the strongest inhibitor among the tested compounds (las activity 0%; rhl activity 0%) 
against both las and rhl systems.127  
The other strategies for modulating QS and effecting production of AI-2, which were 
presented in Table 3, include the novel synthetic analogues of DPD128,129 or the 
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brominated furanoses110-112 and other small molecules that have been recently 
reviewed.129 
An interesting approach for the inhibition of bacterial QS was recently developed by 
Meijler's group which is based on the covalent modification of a QS receptor as a new 
tool to study molecular mechanism of bacterial group behavior and to target bacterial 
virulence. Meijler's group developed isothiocyanate and α-halomethyl carbonyl probes 
which are modified AHL analogues (Figure 24).91  These very reactive isothiocyanate and 
haloacetamide analogues were envisioned to react with proximal nucleophiles via ''azido 
free'' click-chemistry leading to covalent inhibition and molecule labeling. These 
analogues were shown to strongly inhibit P. aeruginosa QS-related gene expression (las) 
resulting in the inhibition of the transcriptional activator LasR.  
 
Figure 24. AHL analogues modified with isothiocyanates and bromoacetamides.91 
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2. RESEARCH OBJECTIVE 
The objective of this dissertation is the design, synthesis and biological evaluation of 
novel LuxS inhibitors which should interfere with quorum sensing processes. My initial 
targets were S-ribosylhomocysteine [SRH] analogues in which the hydroxyl group at C2 
in the ribofuranose ring of the SRH would be substituted by halogens such as bromide or 
fluoride. The two main targets of the C2-substituted sugar analogs are 2-deoxy-2-fluoro-
D-ribosylhomocysteine 36a and its corresponding arabino-epimer 36b as well as 2-
deoxy-2-bromo-D-ribosylhomocysteine 37a and its arabino-epimer 37b (Figure 25). The 
targeted 2-halo-SRH analogues are envisioned to interact with the LuxS protein 
differently than the natural substrate S-ribosylhomocysteine does, upon binding to the 
LuxS enzyme. Thus, 2-halo-SRH analogues, lacking the 2-hydroxyl group, should 
prevent the formation of the 2-keto intermediates (e.g., complex 6, Scheme 3) during the 
interaction with LuxS.  
 
Figure 25. Targeted 2-deoxy-2-halo-S-ribosylhomocysteine analogues. 
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It is postulated that the 2-[F]-SRH analogue 36a after ring opening and abstraction of 
the acidic H2 proton by proximal Cys84 (from the β face) should lead to the formation of 
the fluoro-enol intermediate 36d rather than the 2-keto intermediate which is formed 
during metabolism of the natural SRH (see Scheme 3). 
 
Scheme 9. A possible mechanism of inhibition of LuxS by 2-[F]-SRH. 
The interaction of LuxS with 2-[Br]-SRH analogue 37a might occur by the formation 
of the analogous bromo-enol intermediates or by the nucleophilic displacement of 
bromide. Based on the previous studies with 3-halo-SRH analogues125  (see Scheme 6), it 
is reasonable to expect that after ring opening the reactive α-bromo-ketone intermediate 
37c might be a substrate for nucleophilic substitution by the active site Cys-84 leading to 
a covalent inhibition as depicted in Scheme 10.  
 
Scheme 10. Plausible inhibition of LuxS by 2-[Br]-SRH. 
The displacement of the bromide by cysteinate thiol could occur at either closed or 
opened form of the ribose ring. However, because of the different stereochemical 
41 
 
requirements of the bromo substituent in ribo 37a and arabino 37b substrate, inhibition 
might also shed some light on the leniency of the active site for the stereochemical 
regimen of the substituent at the C2 of the ribose ring. For example, the bromo 
substituent at the β face in the arabino substrate 37b might prevent SN2 displacement 
which requires a nucleophilic attack by Cys84 from the opposite site of the leaving group 
(bromide). The fact that all four 2-halo-2-deoxy-SRH analogues lack the 2-hydroxyl 
group, the first tautomerization step and the generation of the 2-keto-SRH intermediate, 
which is critical for the enzymatic activity of LuxS might be prevented.  
My second targets were SRH analogues in which the hydrogen at C4 of the ribose 
ring is substituted by an alkyl group of varying length (e.g. alkyl, vinyl and aryl; Figure 
26). These 4-C-alkyl-SRH analogues are targeted for two reasons. First, I anticipated that 
4-C-alkyl-[SRH] analogues because of the lack of hydrogen at C4 would prevent the 
elimination of Hcy (as depicted in Scheme 3, conversion 7  → 8) effecting the overall 
production of DPD (Scheme 11). Secondly, since LuxS is a biologically active 
homodimer with a triad interface,102 the addition of an alkyl group could lead to the 
destabilization of the LuxS dimer.  
 
Figure 26. 4-C-alkyl-substituted SRH analogues (4-[R]-SRH). 
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Scheme 11. A plausible mechanism for the inhibition of LuxS by 4-[R]-SRH 
analogues. 
 The next goal of my dissertation was the synthesis of 4-[thia]-SRH mimics (e.g. 
39) in which the furanose ring oxygen has been replaced by a sulfur atom (Figure 27). 
The resulting thiohemiacetal (O,S-acetals) should have different stabilities relative to the 
O,O-acetals present in SRH and as a result different rates of metabolic alteration. The 
expected increased stability of the glycosyl bond should therefore result in decreased 
rates of metabolic degradation and effect production of the open chain aldehyde form 
necessary for the first LuxS-catalyzed isomerization to occur. Moreover, the [4-thia]-
SRH analogues can be converted to a thio-analogue of DPD 39a which could interfere 
with QS because of the different ability for the ring closure (e.g, 39b) and consequently 
different capability of the resulting thiol group to form covalent bonds with borate to 
generate possible thio-analogues of AI-2 signaling molecules. 
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Figure 27. The SRH analogues with furanose ring oxygen substituted by sulfur ([4-
thia]-SRH) and the expected thio-analogues of DPD 
 The last goal in my dissertation is to evaluate the activity of the target compounds 
against LuxS enzyme and to test them as possible quorum sensing modulators of P. 
aeuroginosa and V. harveyi. The significance of this work is to design and synthesize 
new molecules with the capability to interfere with the quorum sensing pathway 
considered as the main communication method among most Gram positive and Gram 
negative bacteria. In vitro and in vivo studies will be necessary to evaluate the molecules 
as an emerging class of antibiotics.  
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3. RESULTS AND DISCUSSION 
3.1 Design and synthesis of 2-halo substituted S-ribosylhomocysteine analogues  
LuxS enzyme might interact with 2-halo-SRH analogues (e.g., 36 or 37) through the 
novel mode of actions. Thus, ring opening of 2-fluoro-SRH substrate 36a and 
complexation of the metallo-Lewis acid with the carbonyl group will make H2 
susceptible to the abstraction by the proximal Cys-84 as presented in complex 36c 
(Scheme 12). The generated in situ fluoroenol 36d might interact with electrophiles 
leading to the alkylation at C2 as depicted in 36e.  
 
Scheme 12. A plausible inhibition of LuxS by 2-[F]-SRH via H2 abstraction. 
In a second mode of action, after a ring opening, Cys-84 might abstract H3 from the 
intermediate 36c which will result in elimination of fluorine in E1cB fashion to produce 
an enone which could further tautomerize to 1,3-dicarbonyl intermediate 36f (Scheme 
13). This 3-keto intermediate could subsequenly undergo β-elimination to release 
homocysteine and produce 3,4-dioxopentanal (DOP) 36g as a highly oxidized analogue 
of DPD (precursor of AI-2). Conversely, abstraction of H3 might happen prior to the ring 
opening leading however to same 1,3-dicarbonyl intermediate. 
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Scheme 13. A plausible inhibition of LuxS by 2-[F]-SRH via H3 abstraction.  
Different stereochemistry at C2 in 2-[F]-arabino-SRH 36b (F is in β-face) might 
preclude abstraction of H2 by Cys-84, which is known from X-ray studies on LuxS to be 
positioned on the  β-face of the substrate, therefore I would expect the attack at C3 to be a 
major pathway of interaction of 2-[F]-arabino-SRH with LuxS.  
In the case of 2-[Br]-SRH, since the bromine is a much better leaving group  than 
fluorine, I expect that direct replacement of bromine by Cys-84 via SN2 mechanism might 
lead to the covalent inhibition by the attack of Cys-84 at C2. The attack might happen at 
the hemiacetal (path 1, Scheme 14) or opened ring form of the bromo-substrate (path 2, 
Scheme 14). The formation of enzyme-inhibitor complexes can be detected using a mass 
spectroscopy technique. 
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Scheme 14. A plausible inhibition of LuxS by 2-[Br]-SRH via SN2 mechanism. 
3.1.1. Synthesis of 2-bromo-2-deoxy-S-ribosylhomocysteine analogues  
The synthesis of the 2-bromo-2-deoxy-SRH 37a was divided into two steps. In the 
first step the 2-bromo-2-deoxyribose precursor 45 was prepared (Scheme 15), while the 
second step was envisioned as the coupling between 45 and the homocysteine thiolate 49. 
The bromo-sugar precursor 45 was prepared according to the literature report.130 It started 
with the oxidation of the 2-deoxyribose 40 with Br2 /H2O to 2-deoxyribonolactone 41. 
The treatment of the resulting 41 with TBDMSCl produced a disilylated ribonolactone 42 
with 80% yield. Direct bromination of 42 with NBS, following the procedure developed 
by Sauve,130 led to the formation of the bromo-lactone 43 as a mixture of arabino/ribo 
epimers in 2:1 ratio. The formation of 43a and 43b was consistent with the bromination 
of the intermediate enolate. However, the obtained mixture of the arabino and ribo-
epimers differed from the reporting in literature (arabino/ribo, 1:1.4)130 ratio. The 
arabino/ribo epimers of 43 were successfully separated using column chromatography. 
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Compound 43 was considered as a precursor for the synthesis of the mesylated 
derivative 45 intended to be coupled with the homocysteine thiolate to afford the desired 
final product 50. Thus, deprotection of 43 with TFA/H2O (9:1) effected selective removal 
of TBDMS group from the primary 5-hydroxyl group of 43 to afford 44 in 90% yield. 
Treatment of 44 with mesyl chloride in pyridine produced the desired 5-O-mesyl 
derivative 45 in 60% yield (Scheme 15). 
 
Scheme 15. Synthesis of the 2-bromo-2-deoxy-5-O-mesyl-ribono/arabinono lactone 
derivatives. 
The protected homocysteine precursor 49 was prepared starting from the 
commercially available L-homocystine 46 following the literature protocol67 (Scheme 
15). Thus, treatment of the homocystine 46 with di-t-butyl dicarbonate gave N-Boc 
protected homocysteine 47. Next, the carboxylic group in 47 was protected as tert-butyl 
ester upon treatment with diisopropylcarbodiimide (DIC) and t-butanol. The reduction of 
the disulfide bond in 48 with triscarboxyethylphosphine hydrochloride (TCEP) followed 
by aqueous workup afforded the homocysteine 49 of the  appropriate purity for the 
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coupling with sugar precursors.  It is noteworthy that employing TCEP124 as water 
soluble reducing agent rather than organic soluble trialkylphosphines67,83 simplified the 
preparation of the protected homocysteine substrate 49.  
 
Scheme 16. Synthesis of homocysteine-thiolate. 
Two methods for the displacement of the mesylate group in the ribonolactone 45 with 
thiolate anion generated from homocysteine 49 were attempted. In the first approach, 
LDA was used as a base and DMF as a solvent. Thus, coupling of 49 and 45 in DMF 
resulted in the formation of the complex reaction mixture. Careful purification of the 
crude reaction mixture on the column chromatography resulted in the isolation of few 
products in low yields which showed no presence of bromine in their mass spectra. 
In the second approach K2CO3 was used as a base and dry acetone as solvent. The 
complex reaction mixture was purified on column chromatography and desired product 
50' was not isolated (Scheme 17).  Proton NMR of the crude reaction mixture showed 
however the characteristic pattern for the protons of homocysteine and sugar moieties. 
Mass spectra analysis of the major fraction, showed no presence of the typical pattern of 
bromine isotopes (M/M+2). 
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 The complexity for the displacement reactions maybe attributed to the fact that the 
bromine at C2 in the ribonolactone precursor 45 (at Cα to ester carbonyl) also is a good 
leaving group and might be involved in nucleophilic substitution reaction with 
homocysteinate salts leading to 50. To prove this hypothesis, I carried out a reaction 
between 45 with model alkyl-thiol. 
  
Scheme 17. Coupling between the 5-O-mesyl-2-bromopentafuranose lactone and 
homocysteine thiolate. 
In order to optimize conditions for the reactions of bromo-lactone 45 with thiols, I 
carried out reactions between 45 and propylthiol instead of homocysteine under different 
conditions. Thus, treatment of 45 (R/S, 60:40) with 1 equiv. of the propylthiolate 
generated from propylthiol/LDA in DMF at 0 0C resulted in the formation of new product 
and disappearance of substrate 45. Purification of the crude reaction mixture on the silica 
column chromatography gave 1:1 mixture of the 2-S-propyl substituted 2-
thioribonolactone 50a (as 1:1 mixture of the arabino/ribo epimers) in overall yield of 
61% (Scheme 18).  Structure for 50a was established based on spectroscopic data. Thus, 
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1H NMR spectra shows the singlet at 3.06 ppm indicative of the presence of the mesyl 
group in addition to the characteristic peaks for the propylthiol moiety. On 13C NMR, 
peaks at 171.47/172.74 ppm indicate the presence of the carbonyl groups in the lactone 
50a for the arabino-ribo epimers, while the lack of the bromine patterns (M/M+2) on 
mass spectra analysis suggested the substitution at C2 and the loss of the bromine 
substituent. These results indicate that the secondary bromine at the α-position to the 
carbonyl group in ribonolactones is a better leaving group than the mesylate at the 
primary hydroxyl group at C5. 
 
Scheme 18. Model reaction of bromo-lactones with propylthiol 
3.1.2. Synthesis of 2-deoxy-2-fluoro-S-ribosylhomocysteine analogues 
Two literature procedures were considered for the preparation of 2-fluoro-2-
deoxypentafuranosyl precursors (e.g., 60, Scheme 19) for the coupling with 
homocysteine. One approach was based on Fox's methodology131 presented in Scheme 
19. It involves the fluorination of allose 53 to fluoroglucose 55 followed by an 
intramolecular rearrangement to yield to 60. The overall synthesis of 60, started with the 
oxidation of 1,2,5,6-di-O-isopropylidene-α-D-glucofuranose 51 with chromium trioxide –
pyridine complex to afford its corresponding ketone 52. Reduction of 52 with sodium 
borohydride is expected to deliver hydride anion at the β-face132 of the sugar ring because 
of stereo-hindrance of the isopropylidene group present at C1 and C2 to give allose 53. 
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Treatment of 53 with DAST resulted in a nucleophilic displacement of the hydroxyl 
group at C3 by fluoride with the inversion of configuration at C3 position to give 3-
fluoroglucose 54.133 Selective deprotection of the isopropylidene group from diol at C5 
and C6 yielded 55 in high yield. Treatment of the latter with benzoyl chloride effected 
selective protection of the primary hydroxyl group at C6 to give 56. Subsequent removal 
of the isopropylidene group in 57 from C1 and C2 by treatment with TFA/H2O gave 6-O-
benzoyl-3-fluoroglucose 57 as an anomeric mixture (α/β, ~1:3). Treatment of 57 with 
NaIO4 effected cleavage of cis-vicinal diol at C1 and C2 to give open sugar 58 which 
underwent simultaneous rearrangement involving a ring closure between the hydroxyl 
group at C5 with the aldehyde group generated at the former C2 (as depicted in 58) 
resulting in overall repositioning of fluorine atom from C3 to C2 leading to 59. Treatment 
of 59 with sodium methoxide yielded the fluoroarabinose 60.  
 
 
Scheme 19. Synthesis of 2-deoxy-2-fluoro-α,D-arabinofuranose 
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The second approach for the synthesis of 2-fluoropentofuranose was based on Cen 
and Sauve130 protocol. In this approach, the fluorination of the protected ribonolactone 42 
is reported to give 2-fluoro-2-deoxy-ribo-lactone 62. The protocol involved enolization of 
lactone 42 with TMSOTf followed by fluorination of the resulting α-silyl lactone 61 
intermediate with NFSi (N-fluorobenzene sulfonamide) to give 2-deoxy-
fluororibonolactone 62 as a single ribo-epimer. The stereoselectivity of the reaction is 
attributed to the diasteroselective formation of α-silyl lactone 61 due to sterically bulky 
TBDMS that prevents the syn approach to the generated in situ enolate. In our hands, 
treatment of 42 with TMSOTf/NFSi gave fluorolactone 62 in lower yields than reported.                      
 
Scheme 20. Synthesis of 2-Deoxy-2-fluororibonolactone 
Having in hand the fluoropentafuranoses sugar precursors  60 and 62, I focused on 
the preparation of the fluoro analogues with (a) 5-hydroxyl group activated for the 
replacement with homocysteine unit and (b) proper protection of other hydroxyl group 
which would be suitable for the coupling procedures which employs bases. Treatment of 
fluororibonolactone 62 with TFA/H2O effected regioselective removal of the silyl 
protection group from the primary hydroxyl group at C5 to give 63. Subsequent 
mesylation of the primary hydroxyl at C5 gave 64; a suitable precursor for the 
displacement reaction with thiolate anion generated from the protected homocysteine. 
However, coupling of 64 with homocysteine 49 (in LDA/DMF) produced a complex 
reaction mixture from which I was not able to isolate a desired product 65. Attempted 
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deprotection of the crude and contaminated 65 with TFA followed by RP-HPLC 
purification failed to yield the desired 2-[F]-SRH 36a (Scheme 21). 
 
Scheme 21. The proposed plan for the synthesis of 2-deoxy-2 fluoro-D-
arabinofuranose. 
3.2. Design and synthesis of 4-C-alkyl/or aryl-S-ribosylhomocysteine analogues 
3.2.1. Rationale for the synthesis of the 4-substituted SRH analogues:  
The substitution of the hydrogen at C4 of the 4-alkyl/or aryl-[SRH] derivatives by an 
alkyl or aryl group should impede the third tautomerization in the LuxS-catalyzed 
reaction and therefore prevent the elimination of the homocysteine molecule by the β-
elimination process (Scheme 22). Thus, inhibition of DPD production should 
theoretically be shut down effecting also the QS communication in bacteria. The 
abstraction of H-atom from C4 by the glutamine amino acid should not occur in the case 
of 4-C-substituted [SRH] derivative (complex 67a). I was also interested in checking the 
differences in the inhibitory activity based on the alkyl group length and chemical nature 
such as alkyl, vinyl, and aryl groups incorporated at C4 of ribose ring. The length of the 
alkyl group might also play an additional role in imposing the dimerization inhibition, 
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especially since LuxS is a dimer protein. Thus, the alteration of the active site of the 
enzyme may lead to an allosteric inhibition. In theory, the longer the alkyl chain 
incorporated a more potent dimerization inhibition of LuxS should be observed by 
making the inhibitor at ease to reach both homodimer parts of the protein. The inhibitor 
might block one monomer leading to the alteration of the activity and as a consequence 
conformational changes of the second monomer.  
 
Scheme 22. A plausible inhibition of LuxS by 4-alkyl/or aryl-[SRH] substrate.        
3.2.2. Synthesis of 4-C-substituted SRH analogs: 
3.2.2.1 Synthesis of 4-C-substituted ribono-1,4-lactones  
Preparation of 4-C-alkyl/aryl-S-ribosylhomocysteine analogues was envisioned to 
proceed through a keto-substrate 73134 suitable for the alkylation with varying Grignard 
reagents. The ribitol-4-ulose 73 was prepared from ribose 68 employing the procedure 
reported by Maddaford.134 Thus, treatment of ribose 68 with acetone in the presence of 
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H2SO4 gave the isopropylidene protected ribofuranose 69 (Scheme 23).135 Tritylation of 
the primary 5-hydroxyl group 69 with TrCl yielded 70. Reduction of the hemiacetal 70 
with NaBH4 provided the acyclic ribitol 71. Subsequent silylation of 71 with TBDMSCl 
effected regioselective protection of the primary hydroxyl group at C1 to give 72. 
Oxidation of the secondary hydroxyl group at C4 of 72 with Dess-Martin periodinane 
reagent provided the 4-ulose derivative 73, as a suitable precursor for the subsequent 
alkylation reactions with Grignard-based reagents. The overall yield for the conversion of 
the ribose 68 to ribitol-4-ulose 73 was 75% (5 steps).      
 
Scheme 23. Preparation of the precursors for the synthesis of 4-C-alkyl-SRH 
analogs.134 
Diastereoselective addition of different Grignard reagents to ketone 73 was 
accomplished following Pryde and coworkers procedure.134 Alkyl, vinyl and aryl 
substituents were successfully inserted at the 4-position of the ribose ring to give a 
variety of 4-substituted ribitols 74a-e (Scheme 24). Thus treatment of ketone 73 with 
methylmagnesium bromide at -78 oC for 15 min produced the corresponding 4-C-methyl-
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ribitol 74a in 88% yield as single isomer after purification on silica gel column. The 1H 
and 13C NMR spectra were diagnostic for the structure of 74a. On the 1H NMR spectrum, 
a new singlet for the methyl group at 1.35 ppm was observed along with the 
disappearance of the signal for H4 and simplification of the multiplets signals for H5 and 
H5' to doublets (as compared to 72) with geminal coupling constants between them of 8.7 
Hz.  Addition of hexylmagnesium bromide or octylmagnesium bromide to ketone 73 
gave the corresponding 4-C-hexyl and 4-C-octyl ribitols 74b and 74c in 64% and 60% 
isolated yields, respectively. Also addition of the vinyl magnesium bromide to ketone 73 
proceeded smoothly to give the 4-C-vinyl-ribitol 74d in 55% yield as a single isomer. 
The characteristic pattern of the peaks for the terminal monosubstituted olefin was 
observed in the 1H NMR spectrum of 74d. The addition of 4-methoxyphenylmagnesium 
bromide to ketone 73 also proceeded efficiently to provide 4-C-aryl ribitol 74e in 96% 
yield. 
 
Scheme 24: Diasteroselective addition of Grignard reagents to the 4-ketoribitol 
precursors. 
The stereoselective formation of 4-C-substituted ribitols 74 can be explained by the 
Cram’s rule for the chelation of heteroatom on the α-carbon to a carbonyl group (Scheme 
25). The Grignard reagent addition to the ribitol-4-ulose 73, which is an α-alkoxy ketone, 
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proceeds via a 5-membered cyclic chelate 73a. Crams’s rule stated that nucleophilic 
addition with either organometallic or metal hydride reagent leads to chelation control in 
diastereoselective carbonyl reduction. The carbonyl is flanked by two smaller groups S 
and M. The larger group L is eclipsed to the carbonyl group. The metal part gets 
complexed with the carbonyl group and the alkanide carbanion is transferred to the 
trigonal carbon from the side of small group in preference to medium group or in the anti-
fashion to the α-hydroxyl group at C3. 
 
Scheme 25. Proposed model for the diastereoseletive addition of the Grignard 
reagent to ketone 73.  
Treatment of 4-C-methylribitol 74a with TBAF in THF at 0 oC for 30 min effected 
selective removal of the TBDMS protection group to give the ribitol 75a in 77% yield. 
Analogous desilylation of 75b-e produced the corresponding 4-C-substituted ribitols in 
77-87% yield for 75b-d and 59% yield for 75e having a primary hydroxyl group at C1 
and a tertiary hydroxyl group at C3. 
With the 4-C-substituted ribitols 75 in hands, I investigated few options for the ring 
closure in order to prepare the suitable 4-substituted ribose precursors for the coupling 
with Hcy. The first option involved oxidation of the primary hydroxyl at C1 in 75 to the 
carboxylic acid with the concomitant ring closure to the corresponding ribono-1,4-
lactone. Thus, the Ley-Griffith oxidation of the primary hydroxyl group at C1 in 75a with 
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tetrapropylammonium perrenthenate (TPAP)/N-methylmorpholine N-oxide (NMO) 
followed by the intramolecular ring closure gave the corresponding 4-C-methyl ribono-
1,4-lactone 76a in 80% yield after silica gel column chromatography. The oxidation of 
75a occurred with catalytic amount of TPAP in the presence of a stoichiometric amount 
of co-oxidant NMO that regenerates the catalyst. The 1H and 13C NMR spectra were 
diagnostic for the structure of 76a. On the 1H NMR spectrum, the disappearance of the 
signals for H1 and H1' and simplification of the signal for H2 to a doublet with vicinal 
coupling constants of 5.6 Hz to H3 was indicative of the oxidation of the hydroxyl group 
at C1 and the formation of lactone. The formation of lactone was also supported by the 
appearance of a peak at 172.07 ppm for the carbonyl carbon at C1 on 13C NMR spectrum.  
Oxidation of 4-C-hexyl and 4-C-octyl ribitols 75b or 75c with TPAP/NMO also 
proceeded smoothly to give the 4-C-hexyl- and 4-C-octylribonolactones 76b and 76c in 
90-95% yield as single isomers. On 1H NMR spectra, the appearance of the doublet of H2 
at 4.1 ppm with a coupling constant of 5.6 Hz was indicative of the ring closure and 
formation of lactones 76b or 76c (Scheme 26). Similarly to 76a a new peak at 174.41 
ppm appeared on 13C NMR proving the presence of the carbonyl group at C1. However, 
depending on the reaction workup conditions, especially for the ribonolactones with long 
alkyl chain, the open form of the ribonolactones 76'b and 76'c with the free carboxylic 
group at C1 were detected. During the oxidation of 75c to 76c the ratio of 76c to 76'c in 
equilibrium was found to be 3:1. The 1H NMR spectrum of the equilibrium mixture of the 
ribonolactone 76c and its opened carboxylic acid form 76'c have two distinctive sets of 
peaks of the ribosylic protons H2, H3, H5 and H5' (see experimental part). The MS 
spectra which differ by 18 units (H2O) were indicative of ring opening of 76'c to 76c. 
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Scheme 26. Oxidation of 4-C-substituted ribitols with TPAP and NMO 
The oxidation of the riitols 75 and intramolecular ring closure to lactone 76 is 
believed to be initiated by the attack of the primary hydroxyl group at C1 on the 
ruthenium oxidant.136 The resulting oxide 77 further abstracts the hydrogen atom from C1 
to form aldehyde 78 (Scheme 27).  Hydration of the aldehyde to 79 and the repetition of 
the oxidation cycle leads to the ring closure and formation of the 4-C-alkylribonolactone 
76, which occurred by a nucleophilic attack of the C4 hydroxyl group on C1, as depicted 
in complex 80, leading to the release of the ruthenium molecule.  
 
Scheme 27: Mechanism of oxidation with NMO/TPAP and ring closure to 
ribonolactone. 
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In a second approach towards ring closure of the 4-C-substituted ribitols 75, I 
examined the possibility of the oxidation of the primary hydroxyl at C1 to an aldehyde, 
which should subsequently cyclizes to the hemiacetal 81 via the intramolecular ring 
closure (Scheme 28). The advantage of this method is that it leads to an already reduced 
sugar 81 instead of a lactone precursor 76. However, attempts to oxidize 75b or 75c 
employing Swern reaction condition (oxalic chloride/DMSO/Et3N) gave a complex 
reaction mixture with low yields and hemiactal 81 has never been isolated from the 
reaction mixture in a pure form (Scheme 28). 
 
Scheme 28. Attempted synthesis of hemiacetals 81 by Swern oxidation. 
3.2.2.2 Coupling of 4-C-substituted 1,4-ribonolactones and Hcy 
With the 4-C-substituted ribonolactones 76a-e in hands, I considered options to 
prepare the suitable 4-substituted ribose precursors for coupling with Hcy (Scheme 29). 
Thus, detritylation of 76a (16 h, rt) with TFA/CH2Cl2 gave 84a in 66% yield after 
purification on silica gel column chromatography. On 1H NMR spectrum of 84a, the 
absence of the aromatic hydrogens between 7.25-7.38 ppm was indicative of the trityl 
group removal. HRMS showed a molecular ion [M+Na]+ peak at 225.0734 verifying a 
molecular formula C9H14O5Na +. 
Analogous treatment of the hexyl 76b and octyl 76c with TFA (5 h, rt) gave 84b and 
84c in 80% and 75% yields, respectively. Interestingly, when the reaction mixture (76b 
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→ 84b) was left stirring overnight, a second product was formed in a ratio of 1:1 to 84b. 
The new product is believed to be the corresponding 4-C-hexylribopyranose 88b formed 
via the ring opening of the ribofuranose 84b and the subsequent ring closure with C5 
hydroxyl group. 1H NMR and COSY spectra of the 1:1 mixture of 84b/88b showed two 
sets of distinctive peaks. A doublet for H2 of 88b was shifted downfield from 4.55 ppm 
to 4.22 ppm. Also, the vicinal coupling constant between H2 and H3 was changed from 
5.6 Hz in 84b to 2.5 Hz in 88b. The magnitude of the geminal coupling constants 
between protons H5 and H5' in 88b (12.7 Hz) were larger than the one observed in 84b 
(11.6 Hz).  Treatment of the vinyl analogue 76d with TFA (5 h, rt) also gave detritylated 
ribonolactone 84d but in only 35% yield after purification on silica gel column 
chromatography. Similarly, 76e was converted to 84e with 60% yield. HRMS spectra of 
compounds 84a to 84e mass spectra were consistent with the theoretical molecular mass 
of respective compounds, which verified that detrytilation occurred.    
In the next step, I considered reduction of the 4-C-substituted fully protected 76b or 
detrytilated 84c ribofuranoses with LiEtBH3 as a valuable approach for the synthesis of 
the cyclic hemiacetal 86, especially since our previous attempts to convert ribitol 75 to 
hemiacetal 81 employing the Swern reaction were unsuccessful as described above. Thus, 
treatment of the 4-C-hexyl 76b with LiEtBH3 in CH2Cl2 at 0 oC for 30 min gave the 
corresponding hemiacetal 86b as an anomeric mixture (α/β, 1:3) in 54% yield after 
column chromatography. The chemical shift and vicinal 3JH1-H2 coupling constant was 
diagnostic for the composition of α/β anomers. For the α-isomer the signal for H1 was 
observed as a doublet of a doublet with splitting to H2 and OH group at C1 with 
respective coupling constants of 4.2, 11.6 Hz. For the β-isomer, the signal for H1 
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appeared as doublet with coupling constant of 8.5 Hz to hydroxyl group only. In addition, 
H2 appeared as a doublet of doublet with couplings to both H1 and H3 in the α-isomer, 
whereas for the β-isomer, the signal fo H2 is simplified to a doublet with a coupling 
constant of 6.0 Hz to H3 only. 
 Analogous treatment of the 4-C-octyl 84c with LiEtBH3 gave the hemiacetals 86c as 
an anomeric mixture: 86c (α/β, 1:1; 63%) after column chromatography (Scheme 29). 
Attempted conversion of the hemiacetals 86b and 86c to the respective methyl riboside 
acetals 87b and 87c upon treatment with either (i) MeOH/acetone for 86b or (ii) 
pTSA/MeOH for 86c failed to produce the desired acetal 87b or 87c. Since acetals are 
stable in basic conditions, they were envisioned as good substrates (after activation of the 
5-hydroxyl group) for the condensation with Hcy which required basic conditions.  
In the next approach for the coupling of 4-C-alkyl riboses with Hcy, I turned my 
attention to the direct coupling of ribono-1,4-lactones with Hcy as a plausible alternative. 
Thus, treatment of 84a, 84b, 84c and 84e with mesyl chloride gave the corresponding 5-
O-mesylribonolactone 85a with 63% yield, 85b and 85c with approximately 50% yield, 
and 85e with 83% yield after column chromatography. On 1H NMR spectra, a singlet at 
3.01 ppm was diagnostic for the presence of the mesyl group at C5 in all compounds. A 
shift of H5 and H5' signals from 3.75 and 3.85 ppm in 84b and 84c to 4.20 and 4.32 ppm 
in 85b and 85c indicated the formation of the mesylate ester. Similarly, a comparable 
downfiled shift of H5 and H5' occurred on 1H NMR spectra in 85a and 85e as a result of 
the introduction of methylsulfonate EWG. 
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Scheme 29. Different strategies of 4-substituted ribose precursors  
Nucleophilic displacement of the mesylate in 85b with Hcy thiolate (3 equiv.), 
generated from the protected L-homocysteine 49 and LDA in DMF, afforded 89b in 65% 
yield after silica gel column purification (Scheme 30).  The structure of the 89b was 
established by the spectroscopic techniques. HRMS (AP-ESI) proved the molecular 
formula of C27H48NO8S+. Analogous coupling of 85c with Hcy gave 89c (~ 30%) 
contaminated with the protected Hcy 49 substrate (~50%) which was used in excess in 
the reaction. The upfield shift of H5 and H5' signals on 1H NMR spectra from 4.20 and 
4.32 ppm in 85b and 85c to 2.72 and 2.80 in 89b and 89c indicated the formation of the 
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new C-S bond. The 4-C-aryl mesylate 85e was coupled with homocysteine thiolate 49 to 
give 89e with 48% yield.  
Treatment of the crude 89c with TFA effected global deprotection of all acid label 
groups to give crude 90c. Purification of the mixture on Sepak column gave 4-C-octyl-
SRH lactone 90c as a 95% pure product in 15% overall yield from 85c. The molecular 
formula for 90c [C17H31NO6S+] was verified by HRMS. Deprotection of 89b with TFA 
gave 90b in 60% yield after HPLC purification. Analogous deprotection of 4-C-4-
methoxyphenyl SRH lactone 89e with TFA and its purification gave 90e. The molecular 
formula for 90b [C15H27NO6S+] and 90e [C16H21NO7S+] were verified by HRMS. 
Treatment of 89b with LiEt3BH/THF (5 equiv.) in CH2Cl2 at 0 0C effected reduction 
of the lactone to the hemiacetal yielding  protected SRH analogue 91b as a mixture of α/β 
anomers (1:4). Deprotection of 91b with TFA and TFA/H2O effected removal of all the 
protection groups to give anomers of 4-C-hexyl-SRH 92b. Similarly, deprotection of 91e 
yielded 92e. Subjection of 89e to the reduction and deprotection sequence afforded 92e. 
Alternatively, the deprotected lactone 90c was reduced with LiEt3BH/THF to afford 
hemiacetal 92c. 
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Scheme 30. Coupling of mesyl-ribonolactone derivative with homocysteine thiolate 
and deprotection  
3.3. Design and synthesis of 4-[thia]-S-ribosylhomocysteine analogues  
Replacement of the sugar ring oxygen by sulfur provides close mimics of natural 
sugars, it is noteworthy, that the sulfur atom is larger and more polarizable than oxygen 
and the carbon –sulfur bond is longer (C-S, 0.182 nm vs C-O, 0.143nm), weaker and less 
polar  than a carbon-oxygen bond (electronegativities on the Sanders scale: O, 3.65; S, 
2.96; C, 2.75).137 Such differences are responsible for significant alterations in the 
anomeric effect, conformational behavior, chemical reactivity, molecular recognition by 
proteins, and metabolic stability of thiosugars analogues in comparison with their oxygen 
counterparts. Since only the open aldehyde form of SRH is catalytically active, I was 
interested in the effect of the sulfur substitution on the ring opening, especially since 
previously has been shown that for 4-[aza]-SRH analogue acted as time-dependent 
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inhibitors of LuxS as discussed in section 1.1.5 (Scheme 27 and 28). The existence of the 
thiohemiacetals in equilibrium with open aldehyde form is expected for 4-thioriboses 
under basic and/or acidic conditions.138 In my efforts to synthesize thiohemiacetal 39 
(Scheme 29), I explored the possibility of employing thioribosyl fluorides as precursors 
for the preparation of the O,S-acetals analogues of SRH. 
The synthetic approach started from 1-deoxy thiosugar precursor 93, which was 
prepared from D-ribose or gulonolactone following the procedures of Mastuda139 or 
Jeong.140,141 Thus, acetylation of the 5-hydroxyl group in 93 gave 94 in 95% yield 
(Scheme 29). Subsequent oxidation afforded sulfoxides 95 as a 4:1 mixture of 
diastereomers at sulfur. Treatment of sulfoxide 95 with DAST/SbCl3 combination142 
resulted in fluoro-Pummerer rearrangement to give α-fluoro thioether 96 (α/β~ 1:9) in 
65% combined yield after flash column chromatography. Reactions of sulfide 94 with 
DAST/SbCl3143 also produced thioribosyl fluorides 96 (β-anomer only in 49% yield), 
demonstrating that oxidation of sulfide to sulfoxide is unnecessary step in the conversion 
of thioethers to α-fluoro thioethers. On 1H NMR spectrum the thioribosyl fluorides 96 
showed a geminal coupling constant between F and H1 (J = 54.0 Hz). 19F NMR spectrum 
of 96 (β-anomer) showed a ddd at δ -140.85 (J = 2.3, 9.5, 54.0 Hz) whereas 19F NMR 
spectrum of 96 (α-anomer) showed a dd at δ -157.24 (J = 15.2, 56.7 Hz). 
Since α-fluoro thioethers are at the carbonyl oxidation level, these thioacetals were 
found to be sensitive to acidic conditions.142 I found out that under slightly acidic 
conditions, such as silica gel, a spontaneous hydrolysis of α-fluoro thioethers 96 occurred 
to yield thiohemiacetals 99, as was proven by the loss of the fluoride signal in the 19F 
NMR. Since on the other hand α-fluoro thioethers are relatively stable to basic 
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conditions, in parallel with acetals, I discovered that treatment of 96 (β-anomer) with 
methanolic ammonia effected deacetylation providing 97 as a single β-anomer. The 
fluoride 97 was then mesylated at primary hydroxyl to give reasonable stable 98. I was 
fortunate to find that coupling of 98 with protected Hcy (scheme 29) indeed afforded 
relatively stable 4-[thia]-SRH fluoride 100. Since the presence of moisture and slightly 
acidic conditions cause hydrolysis of thioribosyl fluoride to thiohemiacetals, attempted 
purification of the crude 100 on silica gel column yielded separable mixture of 100 (25% 
yield) and protected 4-[thia]-SRH derivative 101 as a single β anomer (27% yield). The 
structure of the 4-[thia]-SRH fluoride 100 was established by spectroscopic techniques. 
HRMS (AP-ESI) proved the molecular formula of C21H36FNNaO6S2 [M+Na]+ (m/z 
504.1847). Treatment of 100 with aqueous TFA effected hydrolysis of fluoride as well as 
removal of the N-Boc, acetonide, and t-butyl ester protection groups in a single step to 
give 4-[thia]-SRH derivative 39 in 91% yield as a mixture of anomers whose α:β 
anomeric ratio changed when stored in D2O from 1:1 → 1:4. Also acid catalyzed 
deprotection of 101 also led to the formation of 39. The structure of the 4-[thia]-SRH 39 
was established by spectroscopic techniques. HRMS (AP-ESI) proved the molecular 
formula of C9H16NO5S2 [M-H]- (m/z 282.0484). 
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Scheme 31. Synthesis of [4-thia]-SRH analogue. 
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3.4 Biological activities 
3.4.1. Inhibition of LuxS enzyme 
Interaction of the 4-C-alkyl/aryl-SRH lactose 90 and hemiacetals 92 will be studied in the 
collaboration with Professor Pei in Ohio State University and the results will be 
published elsewhere.  
3.4.2. Screening against rhl and las in P. aeruginosa QS 
AI-2, known as the universal signaling molecule in bacteria144 with a known X-ray 
crystallographic1 structure in complex with LuxP, has been targeted by different 
researchers.    Meijler and coworkers.109 studied a panel of DPD analogues with 1 carbon 
increment in the alkyl chain at C2 (Figure 28). The extension in the alkyl group unit was 
thought to alter ligand induced conformational changes without changing the receptor-
ligand affinities. Results showed that the presence of DPD, the synthesized DPD 
analogues acted as agonists, increasing luminescence in the V. Harveyi. Two theories 
were drawn from these findings: either (i) the analogues are allosterically interacting with 
the AI-2 receptor LuxP but only when DPD is present or (ii) they bind to an alternative 
site resulting in increased gene expression and DPD increased DPD induction. In order to 
further examine the preceding results, Ganin and coworkers focused on P. aeruginosa as 
a bacterium of choice to test their compounds since it is a bacterium that responds to AI-2 
but does not synthesize DPD by itself. Results showed that significant inhibition of 
luminescence occurred with butyl and pentyl-DPD with a maximum of 40% inhibition at 
200 µM for both.   
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Figure 28. Alkyl-DPD analogues.109 
To search for the effects of non-native AHL scaffold on QS, I have also tested the 4-
C-alkyl/aryl-SRH and 4-[thia]-SRH analogues against the P. aeruginosa QS. The 
different analogues were designed in a way to resemble SRH known to regulate QS 
through the LuxS-mediated biosynthesis of AI-2. In 4-[thia]-SRH analogues (39, Figure 
29), the oxygen in the ribose unit is replaced by a sulfur atom or the sulfoxide moeity.  
 
Figure 29. Thia-S-ribosyl-L-homocysteine analogues screened for their anti-QS 
activity and bacterial growth. 
It is noteworthy to add that very recently a team of Dr Bassler and Dr Semmelhack 
reported novel thio-homoserine analogues: meta-chloro-thiolactone (mCTL) 104a and 
meta-bromo-thiolactone (mBTL) 104b (Figure 29) which were able to act as inhibitors of 
Pseudomonas aeruginosa QS and prevent biofilm formation and production of virulence 
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factor.145 These compounds have similar structure to the lactams prepared by Malladi or 
the thiolactone analogues synthesized in this dissertation. The main difference is that the 
compounds synthesized by Malladi126 and in this dissertation, have a bulky Hcy fragment 
for 5-S-alkyl unit at C4 of the sugar ring while Bassler's new thiolactone analogues has 
the modified acetylated amino-fragment attached to C2. 
 
 
Figure 30. Structure of meta-chloro/or bromo-thiolactone 
To determine the effect of the 4-[thia]-SRH analogues on the P. aeruginosa las and 
rhl AHL-mediated pathways, las and rhl- dependent β-galactosidase were expressed with 
their respective receptor proteins by Dr Kalai Mathee's research group at FIU.146 With the 
collaboration with Dr Mathee's laboratory, 4-[thia]-SRH compounds were tested against 
las and rhl, the AHL treated controls (3-oxo-C12-AHL in case of las and C4-AHL in case 
rhl) were in absence of inhibitors as 100% active (no activity was observed when AHL 
was absent). 
Screening against rhl signaling 
I found that 4-[thia]-SRH (39) did not show any effect on rhl gene function (110% rhl 
activity at 200 µg/mL). The same lack of inhibitory effect was observed for the 1-deoxy-
[thia]-SRH analogue (102). From a pair of diasterioselectively pure sulfoxide, it was 
found that isomer (S) at the sulfur atom in 103b has more inhibitory potential than the 
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isomer (R). At 100 µg/mL the rhl activity was 85% compared to 125% for 103a. The 
racemic mixture showed a median effect of 110% activity for 100 µg/mL of 103c 
concentration. 
 
Figure 31. Effect of 4-thio-SRH analogues on rhl expression in P.lasI-lacZ expression 
in E.coli (p- value ‹ 0.05). 
Screening against las signaling 
As for their effect on las gene, all the preceding 4-thiofuranosides showed in general 
a significant concentration dependent inhibitory effect. The most potent among others 
was  sulfoxide 103b that decreased the activity of las to 40% at 200 µg/mL concentration. 
Similar result was observed for the racemic mixture 103c which exhibited 35% las 
activity for 200 µg/mL concentration. The thioethers 39 and 102 had comparable 
inhibitory activity (55% las activity at 200 µg/mL concentration).  
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Figure 32. Effect of 4-thio-SRH analogues on las expression in P.rhlAI-lacZ expression 
in E.coli (p- value ‹ 0.05). 
With the collaboration with Dr Makemson, the 4-[thia]-SRH analogues were also tested 
for their effect on QS mediated luminescence of wild-type V. harveyi. It was found that 
none of the tested compounds had any effect on bioluminescence. Most of the 
compounds had slight inhibition of the QS but not on total growth of the bacteria. In fact, 
103b and 103c had a slight stimulatory effect. 
 P. aeruginosa V. harveyi 
Compound Anti-QS 
activity 
against LasR 
Anti-QS 
activity 
against Rhl 
Bioluminescence QS Growth 
39 inhibition no effect  no effect  slight 
inhibition  
no effect  
102 inhibition no effect no effect  less than 
50% 
inhibition 
no effect  
103a slight 
inhibition 
no effect - - - 
103b inhibition no effect no effect  slight 
inhibition  
slight 
stimulatory 
103c inhibition no effect no effect  slight 
inhibition  
slight 
stimulatory 
 
Table 5. Anti-QS activity and bacterial growth of 4-[thia]-SRH derivatives. 
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4. EXPERIMENTAL SECTION 
4.1. General Procedures 
The 1H (400 MHz),13C (100 MHz), or 19F (376 MHz) NMR spectra were recorded at 
ambient temperature in solutions of CDCl3 or MeOH-d4 or D2O, as noted. Mass spectra 
(MS) were obtained with atmospheric pressure chemical ionization (APCI) or ESI 
technique and HRMS in AP-ESI or TOF-ESI mode. The reactions were followed by 
TLC with Merck Kieselgel 60-F254 sheets and products were detected with a 254 nm 
light or with Hanessian’s stain.  Column chromatography was performed using Merck 
Kieselgel 60 (230-400 mesh). The purity of the newly synthesized compounds was 
determined to be ≥95% by elemental analysis (C, H, N) and/or HPLC on X-terra® RP-
C18 with gradient program using CH3CN/H2O as mobile phase. Reagent grade 
chemicals were used and solvents were dried by reflux distillation over CaH2 under 
nitrogen gas, unless otherwise specified, and reactions carried out under Ar atmosphere. 
The compounds synthesized in my dissertation are considered, where possible, as 
sugar derivatives or SRH analogs thus the numbering of carbons followed carbohydrate 
nomenclature with anomeric carbon (or the precursor to anomeric carbon) designated as 
C1 (Figure 33). 
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Figure 33. Numbering of the carbons in S-ribosylhomocysteine analogues and the 
corresponding sugar precursors used for the nomenclature of compounds and 
description of their NMR spectra. 
The following General Procedures have been used to describe synthesis of targeted 
compounds: 
Procedure A: Regioselective mesylation of the primary 5-hydroxyl group 
Procedure B: Step a: Preparation of the protected homocysteine; Step b: Coupling of the 
homocysteine with the sugar precursor in the presence of K2CO3 
 Procedure C: Addition of the Grignard reagents to the ribitol-4-ulose 
Procedure D: Deprotection of TBDMS group with TBAF 
Procedure E: Oxidation of the primary hydroxyl with NMO/TPAP and ring closure to 
the lactones, 
Procedure F: Removal of the 5-trityl protection group 
Procedure G: Coupling of the homocysteine with the sugar precursors in the presence of 
LDA 
Procedure H: Removal of the Boc, t-BuO ester and isopropylidene protection groups 
with TFA and TFA/H2O 
Procedure I: Reduction of the lactones to hemiacetals with LiEt3BH 
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4.2. Synthesis of the inhibitors and their spectroscopic characteristization  
2-Deoxy-D-ribonolactone (41). The 2-deoxyribose 40 (1.03 g, 7.45 mmol) was 
added to a solution of Br2 (2 mL) in water (6 mL). The mixture was kept stirring at 
ambient temperature for 5 days and then silver carbonate was added to neutralize the 
mixture to pH = 7. The mixture was filtered and the filtrate was concentrated under 
reduced pressure to yield to yellow oil. The volatiles were evaporated and the sample was 
dried under vacuum to give 41130 (1.02 g, 90%): 1H NMR (CDCl3) δ 2.59 (dd, J = 3.0, 
18.6 Hz, 1H, H2'), 3.05 (dd, J = 3.0, 18.6 Hz, 1H, H2), 3.81 (dd, J = 4.5, 12.9 Hz, 1H, 
H5'), 3.92 (dd, J = 3.1, 12.9 Hz, 1H, H5), 4.50-4.60 (m, 2H , H3, H4). 
2-Deoxy-3,5-di-O-(tert-butyldimethylsilyl)-D-ribonolactone (42). Imidazole (2.5 g, 
37.3 mmol) and TBDMSCl (4.5 g, 29.8 mmol) were added to compound 41 (1.0 g, 7.57 
mmol) dissolved in anhydrous DMF (20 mL). The mixture was stirred at ambient 
temperature for 1 day and quenched by the addition of water. The water layer was 
extracted with EtOAc (3 x 10 mL) and the organic layers were combined, washed with 
brine and dried with anhydrous Mg2SO4 and evaporated. The remaining residue was 
column chromatographed (90% hexane/EtOAc) to give  42130 (750 mg, 80%): 1H NMR 
(CDCl3) δ 0.08-0.10 (m, 12H), 0.80-0.91 (s, 18H), 2.35 (dd, J = 2.6, 17.6 Hz, 1H, H2), 
2.80 (dd, J =  6.7, 17.6 Hz, 1H, H2'), 3.74 (dd, J = 2.5, 11.4 Hz, 1H, H5), 3.78 (dd, J = 
3.2, 11.5 Hz, 1H, H5'), 4.30-4.32 (m, 1H, H3), 4.46-4.81 (m, 1H, H4). 
2-Bromo-2-deoxy-3,5-di-O-(tert-butyldimethysilyl)-D-ribonolactone (43a) and 2-
bromo-2-deoxy-3,5-di-O-(tert-butyldimethysilyl)-D-arabinonolactone (43b). 
Triethylamine (0.42 mL, 303 mg, 3.0 mmol) and TMSOTf (333 mg, 1.5 mmol) were 
added to a stirred solution of 42 (180 mg, 0.50 mmol) in CH2Cl2 (6 mL) at 0 oC for 30 
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min. A solution NBS (134 mg, 0.75 mmol) in 1.5 mL of CH2Cl2 was added and the 
mixture was kept stirring for 1 h at 0 0C. The volatiles were evaporated and the residue 
was washed with saturated NaHCO3 and extracted with CH2Cl2. The combined organic 
layer was washed with brine, dried with anhydrous Mg2SO4 and silica gel column 
chromatographed (85% hexane/EtOAc) to give a mixture of ribo:arabino epimers 
43a/43b130 (1:2; 167 mg, 76%). Ribo-epimer had: 1H NMR (CDCl3) δ 0.08-0.10 (m, 
12H), 0.80-0.91 (s,18H), 3.75 (dd, J =  2.0, 6.4 Hz, 1H, H5), 3.95 (dd, J =  2.3, 4.9 Hz, 
1H, H5’), 4.17-4.22 (m, 1H, H4), 4.38-4.40 (m, 1H, H3), 4.65 (t, J = 6.0, 12.7 Hz, 1H, 
H2). Arabino-epimer had: 1H NMR (CDCl3) 0.08-0.10 (m, 12H), 0.80-0.91 (m, 18H), 
3.77 (dd, J = 3.0, 6.2 Hz, 1H, H5), 3.90 (dd, J= 2.2, 4.8 Hz, 1H, H5'), 4.27-4.32 (m, 1H, 
H4), 4.36 (d, 1H, J = 4.9 Hz, 1H, H3), 4.46 (d, J = 5.6 Hz, 1H, H2). MS (ESI+) m/z 456 
(98, M+NH4+, [79Br]), 458 (100, M+NH4+, [81Br]). 
2-Bromo-2-deoxy-3-O-tert-butyldimethysilyl-arabinonolactone (44). A solution of 
43b (25 mg, 0.05 mmol) in TFA/H2O (2 mL, 9:1) was stirred for 1 h at 0 oC. Volatiles 
were evaporated and the residue was co-evaporated with toluene (0.1 mL). Purification of 
the residue on flash column chromatography column (hexane/EtOAc, 85:15) gave 44 (19 
mg, 90%): 1H NMR (CDCl3) δ 0.17 & 0.20 (2 x s, 2 x 3H), 0.90 (s, 9H), 3.76 (d, J = 12.8 
Hz, 1H, H5), 4.08 (d,  J = 13.0 Hz, H5'),  4.20-4.31 (m, 1H, H4), 4.44 (t, J = 5.8, 11.5 Hz, 
1H, H3), 4.48 (d, J =5.6 Hz, 1H, H2); 13C NMR (CDCl3) δ -5.78, -6.06 (Si-Me2), 22.16 
(C-Me3), 25.71 (C-Me3), 44.85 (C2), 58.41 (C5), 67.26 (C3), 83.23 (C4), 169.55 (C1). 
MS (ESI+) m/z 342 (98, M+NH4+, [79Br]), 344 (100, M+NH4+, [81Br]). 
2-Bromo-2-deoxy-3-O-tert-butyldimethysilyl-5-O-mesyl-arabinonolactone (45). 
Procedure A: TEA (42 µL, 30 mg, 0.29 mmol) and MsCl (9.3 µL, 13 mg, 0.11 mmol) 
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were added to a stirred solution of 44 (34 mg, 0.104 mmol) in dry CH2Cl2 (1.75 mL) at 0 
oC (ice-bath) under N2 atmosphere. After 5 min, the ice bath was removed and the 
reaction mixture was partitioned between CH2Cl2 and diluted HCl. The separted organic 
layer was then washed with aqueous solution of NaHCO3 and brine and was then dried 
over anhydrous MgSO4.  Column chromatography (85% hexane/EtOAc) gave 45 (26 mg, 
60%): 1H NMR (CDCl3) δ 0.17 & 0.20 (2 x s, 2 x 3H), 0.90 (s, 9H), 3.06 (s, 3H), 4.28 (t, 
J = 5.8, 12.7 Hz, 1H, H3), 4.36 (d, J = 5.9 Hz, H2), 4.40 (dd, J = 3.0, 12.0 Hz, 1H, H5), 
4.47-4.50 (m, 1H, H4), 4.56 (dd, J = 2.2, 12.1 Hz, 1H, H5'); MS (ESI+) m/z 451.9 (98, 
M+NH4+ +CH3OH, [79Br]), 453.9 (100, M+NH4++CH3OH, [81Br]). 
2-Deoxy-3-O-tert-butyldimethysilyl-2-[(tert-butoxycarbonyl)-L-homocysteine 
tert-butyl ester]arabinonolactone (50). Procedure B. Step a. H2O (0.45 mL) and tris(2-
carboxyethyl)phosphine hydrochloride (70 mg, 0.24 mmol), were added to a stirred 
solution of N',N'-di(tert-butoxycarbonyl)-L-homocystine di(tert-butyl) ester67 48 (100 mg, 
0.17 mmol) in anhydrous DMF (5 mL) at room temperature under Ar atmosphere. After 
24 hours, the reaction mixture showed on TLC (80% hexane/EtOAc) the conversion of 
the disulfide moiety into a thiol 49. The reaction mixture was partitioned between 
NAHCO3/H2O and ethyl acetate. The organic layer was separated and was washed with 
brine, dried (MgSO4) and was evaporated to give 4967 (98 mg, 99%) as a colorless oil of 
sufficient purity to be used in the next step: 1H NMR (CDCl3) δ 1.40 (s, 10H), 1.51 (s, 
10H), 1.9 (m, 1H), 2.09-2.12 (m, 1H), 2.6 (m, 1H), 4.30 (d, J = 5.2 Hz, 1H), 5.10 (d, J = 
7.6 Hz, 1H, NH). Step b. K2CO3 (40 mg, 0.29 mmol) was added to a stirred solution of 45 
(20 mg, 0.05 mmol) and 49 (14.2 mg, 0.04 mmol) in dry acetone (5 mL). The 
heterogeneous mixture was refluxed for 1 h under argon atmosphere. Volatiles were 
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evaporated and the residue was partitioned between EtOAc (10 mL) and NaHCO3 (10 
mL). The combined organic layer was evaporated and the residue was column 
chromatographed (80% hexane/EtOAc) to give 50 (5 mg, 20%): 1H NMR (CDCl3) δ 
0.08-0.10 (m, 6H), 0.80-0.91 (s, 9H), 1.39 (2 x s, 18 H), 1.90 - 2.11 (m, 2H, H7, H7'), 
2.25 - 2.40 (m, 2H, H6, H6'), 3.01 (s, 3H, Ms), 4.15- 4.25 (m, 1H, H8), 4.70 (d, J = 3.2 
Hz, 1H, H2), 5.00 (d, J =2.5, NH), 5.30 (''t'', 1H, H3); 13C NMR (CDCl3) δ 8.62 (SiMe2), 
14.16 (NCMe3), 21.00 (OMe3), 22.65 (C7), 23.09 (C6), 29.57 (SiCMe3), 32.12 (SiCMe3), 
37.00 (Ms), 46.03 (CH-NBoc), 46.76 (C2), 60.38 (C5), 66.69 (C3), 163.73(CO), 171.15 
(CO), 180.0 (CO). 
5-O-Mesyl-3-O-tert-butyldimethylsilyl-2-S-propyl-2-thioribonolactone (50a). LDA 
(2 M/THF and heptanes, 20 µl, 0.04 mmol) was added slowly to a stirred solution of 
propylthiol (3.8 mg, 0.05 mmol) in anhydrous DMF (2 ml) under Ar atmosphere at 0 oC 
(ice bath). After 30 min, a solution of 45 (10 mg, 0.02 mmol) in DMF (2 mL) was added 
by a syringe and the mixture was continued to stirr for 1 h at 0 oC then at room 
temperature for 24 hours. The TLC showed the formation of new less polar product. The 
reaction was quenched with NH4Cl and the volatiles were evaporated under high vaccum. 
The residue was partitioned between EtOAc and NaHCO3, and the organic layer was 
washed with brine and dried with anhydrous MgSO4. The resulting oil was column 
chromatographed (7:3, hexane/EtOAc) to give 50a as a mixture of two isomers (α:β, 1:1; 
6 mg, 61%): 1H NMR (CDCl3) δ 0.08-0.10 (m, 12H), 0.80-0.91 (s, 18H), 1.10 (t, J =6.6 
Hz, 6H, 2 x Me), 1.45-1.47 (m, 4H, 2 x 2H), 2.45-2.48 (m, 4H, 2 x CH2S), 3.06 (s, 6H, 2 
x Me), 3.20 (d, J = 5.5 Hz, 1H, H2), 3.45 (d, J = 6.4 Hz, 1H, H2), 4.05 (t, J = 3.2 Hz, 1H, 
H3), 4.17 (dd, J = 3.6, 12.1 Hz, 1H, H5), 4.22-4.25 (m, 1H, H4), 4.26-4.33 (m, 2H, H5 
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and H5'), 4.34 (t, J= 2.7 Hz, H5'), 4.38 (t, J = 2.2 Hz, 1H, H4), 4.40 (t, J = 6.8 Hz, 1H, 
H3). 13C NMR -5.18 & -4.25 (Si-(Me)2), 14.15 & 14.21 (Me), 17.84 & 18.11 (CH2), 
21.09 & 22.67 (Si-C-(Me)3), 25.60 (Si-C-(Me)3), 31.61 & 33.71  (CH2), 37.78 & 37.89  
(S-Me), 48.81 & 60.43 (C2),  66.09 & 66.38  (C3), 69.61 & 73.81 (C5), 8.73 & 82.25 
(C4), 171.47 &172.74 (CO).  
6-Deoxy-3-fluoro-1,2-O-isopropylidene-α-D-glucofuranose (55).  A solution of 
54131,133 (0.02 g, 0.076 mmol) in dioxane (0.24 mL) and ethanol (0.12 mL) in the 
presence of H2SO4 (5 M, 0.04 mL) was stirred at room temperature for 4 h. The reaction 
was then neutralized with Na2CO3 and extracted with CH2Cl2. The organic layer was 
washed with brine, dried and evaporated to give 55131 (19 mg, 90%) of sufficient purity 
to be directly used in the next step: 1H NMR (CDCl3) δ 1.30 (s, 3H), 1.50 (s, 3H), 3.81 
(dd, J = 5.0, 11.3 Hz, H6'), 3.90 (dd, J = 3.2, 11.4 Hz, H6), 3.95-4.01 (m, 1H, H5), 4.20 
(ddd, J = 2.2, 8.5, 29.4 Hz, 1H, H4), 4.70 (dd, J = 3.7, 10.8 Hz, 1H, H2), 5.10 (dd, J = 
2.2, 50.2 Hz, 1H, H3), 5.90 (d, J = 3.7 Hz, 1H, H2); 19F NMR δ  -208.11 (ddd, J = 10.9, 
29.3, 50.0 Hz).  
6-O-Benzoyl-3-deoxy-3-fluoro-1,2-O-isopropylidene-α-D-glucofuranose (56). 
Benzoyl chloride (0.1 mL, 130 mg, 0.92 mmol) was added dropwise to a stirred solution 
of 55 (200 mg, 0.9 mmol) in dry pyridine (2.5 mL) and CH2Cl2 (0.9 mL) at -15 oC under 
N2 atmosphere. After 3 h, volatiles were removed and the residue was dissolved in CHCl3 
(2 mL). The resulting solution was washed with saturated NaHCO3 aquous solution (3 x 
1.5 mL), water (2 x 1.5 mL), dried (Na2SO4) and evaporated to give 56131 (61 mg, 34%) 
as colorless solid: 1H NMR (CDCl3) δ 1.30 (s, 3H), 1.50 (s, 3H), 4.10-4.15 (m, 1H, H5), 
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4.18-4.21 (m, 1H, H4), 4.40 (dd, J = 10.0, 11.8 Hz, 1H, H6), 4.61-4.67 (m, 2H, H2, H6'), 
5.10 (dd, J = 2.0, 49.4, 1H, H3), 6.01 (d, J = 3.7 Hz, 1H, H1), 7.41-7.92 (m, 5H, Ar). 
6-O-Benzoyl-3-deoxy-3-fluoro-D-glucofuranose (57). TFA/H2O (9/1, 1.5 mL), was 
added to dry 56 (31 mg, 0.97 mmol) and left stirring for half hour at 0 oC (ice-bath) then 
left for an additional half hour at ambient temperature. The volatiles were co-evaporated 
with toluene then dried to give a mixture of α:β isomers compound 57a/57b131 (1:3; 26 
mg, 92%): 1H NMR (CDCl3) δ 3.70-3.80 (m, 2H, H2, H6'), 4.10-4.17 (m, H5, 1H), 4.45-
4.75 (m, 2H, H3, H6), 4.65 (''t'', J = 9.1, 18.0, H4, 1H), 5.30 (s, 0.5H, H1; β-isomer), 6.01 
(d, J = 3.1 Hz, 0.5H, H1; α-isomer), 7.41-7.92 (m, 5H, Ar). 19F NMR δ  -195.65 (dt, J = 
4.7, 54.7 Hz), -200.60 (dt, J = 11.8, 53.6 Hz).  
6-O-Benzoyl-2-deoxy-2-fluoro-D-arabinofuranose (60). Step a. NaIO4 (23 mg, 0.10 
mmol) was added to a stirred solution of 57131 (23 mg, 0.08 mmol) in water (3 mL) at 
ambient temperature and left overnight. The mixture was then extracted with chloroform 
(30 mL), the organic layer was dried over anhydrous MgSO4. Step b. The crude material 
from Step a (25 mg) was dissolved in MeOH (2 mL) and MeONa (3 mg, 0.05 mmol) was 
added. The resulting mixture was stirred at ambient temperature for 1 h. The volatile 
were evaporated and the residue was column chromatographied (30% hexane/EtOAc) 
gave a mixture of α:β isomers 60a/b (1:9; 20 mg, 86%). The major anomer had: 1H NMR 
(CDCl3) δ 4.25 (d, J = 9.2, 1H, H4), 4.45 (m, 2H, H6, H6'), 4.6 (s, 1H), 5.01 (d, J = 49.8, 
H2, 1H), 5.40 (dd, H3, J = 3.3, 20.7 Hz, 1H),  5.65 (d, J = 10.8 Hz, H1), 7.41-7.92 (m, 
5H, Ar). 19F NMR δ -190.58 (ddd, J = 11.1, 21.8, 49.2 Hz, 0.9F) and δ -190.94 (ddd, J = 
10.8, 19.6, 54.0 Hz, 0.1F). 
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2,3-O-Isopropylidene-5-O-trityl-D-ribitol (71). NaBH4 (4.0 mg, 0.10 mmol) was 
added to a stirred solution of 70134,147 (30 mg, 0.07 mmol) in EtOH (1 mL) at 0 oC (ice-
bath) under N2 atmosphere. After 1 h, the reaction mixture was partitioned between 
NaHCO3/H2O and EtOAc (15 mL).The organic layer was dried over anhydrous MgSO4 
and evaporated. The residue was column chromatographied (30% hexane/EtOAc) to give 
71134 (25 mg, 83%):  1H NMR (CDCl3) δ 0.08 (s, 6H, 2 x CH3), 2.96 (d, J = 3.6 Hz, 1H), 
3.08 (dd, J = 5.0, 8.4 Hz, 1H), 3.34 (dd, J = 6.9, 9.8 Hz, 1H), 3.50 (dd, J = 2.9, 9.8 Hz, 
1H), 3.75-7.81 (m, 1H), 3.83-3.91 (m, 2H), 4.10-4.75 (m, 1H), 4.33-4.40 (m, 1H), 7.25-
7.38 (m, 15H, Ar).  
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-5-O-trityl-D-ribitol (72). 
TBSMSCl (139 mg, 0.92 mmol) and imidazole (93.9 mg, 1.38 mmol) were added to a 
solution of 71 (200 mg, 0.46 mmol) in DMF (4 mL) at room temperature and stirring was 
continued for 72 h. The volatiles were evaporated and the residue was partitioned 
between saturated NH4Cl/H2O and EtOAc. The separated organic layer was then washed 
with NaHCO3/H2O, dried over Mg2SO4, evaporated and the resulting residue was column 
chromatographed (50% hexane/EtOAc) to give 72134 (180 mg, 71%) as an amorphous 
white powder: 1H NMR (CDCl3) δ 0.08 (s, 6H, SiMe2), 0.81 (s, 9H, Si-C-Me3), 1.20 (s, 
6H, 2 x Me), 3.20 (dd, J = 5.3, 9.7 Hz, 1H, H5), 3.25 (dd,  J = 2.8, 9.7 Hz, 1H, H5'), 3.49 
(dd, J = 4.1, 10.6 Hz, 1H, H1), 3.68 (dd, J = 8.7, 10.5 Hz, 1H, H1'), 3.79-3.81 (m, 1H, 
H4), 4.13-3.15 (m, 1H, H2), 4.22 (dd, J = 5.5, 9.2 Hz, 1H, H3), 7.25-7.38 (m, 15H, Ar). 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-5-O-trityl-D-ribitol-4-ulose (73). 
Dess-Martin reagent (15 wt% solution/CH2Cl2; 3.0 mL, 492 mg, 1.16 mmol) was added 
to a solution of 72 (320 mg, 0.58 mmol) in CH2Cl2 (8 mL) at room temperature and 
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stirred for 3 h. The reaction mixture was partitioned between 0.5 mL Na2S2O3 in 10 mL 
of H2O and 10 mL NaHCO3 and CH2Cl2 (15 mL). The organic layer was dried over 
anhydrous MgSO4 and evaporated. The residue was column chromatographied (85% 
hexane/EtOAc) to give 73134 (290 mg, 91%) as an oil: 1H NMR (CDCl3) δ 0.08 (s, 6H, 
SiMe2), 0.81 (s, 9H, Si-C-Me3), 1.35 (s, 3H, Me), 1.37 (s, 3H, Me), 3.68 (dd, J = 4.2, 11.2 
Hz, 1H, H1), 3.76 (dd, J = 4.0, 11.2 Hz, 1H, H1'), 4.04 (d, J =17.7 Hz, 1H, H5), 4.20 (d, J 
= 17.8 Hz, 1H, H5'), 4.51-4.53 ( m, 1H, H2), 4.71 (d, J = 7.8 Hz, 1H, H3), 7.25-7.38 (m, 
15H, Ar). 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-4-C-methyl-5-O-trityl-D-ribitol 
(74a). Procedure C. MeMgBr (1 M/THF,  2 mL, 2.0 mmol) was added to a stirred 
solution of 73 (205 mg, 0.37 mmol) in anhydrous THF (4 mL) at -78 oC under N2 
atmosphere. After 15 min, the reaction mixture was allowed to warm up to ambient 
temperature and was kept stirring for 1 h. The reaction was then quenched by the addition 
of MeOH (1 mL) and diluted with EtOAc (10 mL). The resulting mixture was washed 
with 0.1N HCl and the organic layer dried over anhydrous MgSO4. Volatiles were 
evaporated and the crude residue was then purified by flash column chromatography (90% 
hexane/EtOAc) to give 74a134 (180 mg, 85%) as an clear oil: 1H NMR (CDCl3) δ 0.08 (s, 
6H, SiMe2), 0.81 (s, 9H, Si-C-Me3), 1.35 (s, 3H, Me, C1a), 1.40 (2 x s, 2 x 3H, 2 x Me), 
3.01 (d, J = 8.7 Hz, 1H, H5), 3.12  (d, J = 8.7 Hz, 1H, H5'), 3.25 (dd, J = 3.8, 10.9 Hz, 
1H, H1), 3.70 (dd, J= 3.8, 10.9  Hz, 1H, H1'), 3.90-3.95 (m,1H, H2), 4.40 (d, J = 5.5 Hz, 
1H, H3), 7.25-7.38 (m, 15H, Ar). HRMS calcd for C34H46O5NaSi+ [M+Na]+ 585.3007, 
found 585.3009. 
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1-O-tert-Butyldimethysilyl-4-C-hexyl-2,3-O-isopropylidene-5-O-trityl-D-ribitol 
(74b). Treatment of 73 (160 mg, 0.29 mmol) with hexyl-MgBr (0.8 M/THF; 1 mL, 0.80 
mmol) by Procedure C (flash column chromatography; 80% hexane/EtOAc) gave 74b 
(120 mg, 64%) as a clear oil: 1H NMR (CDCl3) δ 0.08 (s, 6H, SiMe2), 0.81 (s, 9H, Si-C-
Me3), 0.89 (t, J= 6.6 Hz, CH3, C6a ), 1.30-1.40 (m, 8H, C2a-C5a), 1.40 (s, 3H, Me), 1.50 
(s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 3.06 (d, J = 8.9 Hz, 1H, H5), 3.22 (d, J = 8.9 Hz, 
1H, H5'), 3.28 (dd, J = 3.8, 11.1 Hz, 1H, H1), 3.72 (dd, J = 7.6, 11.0 Hz, 1H, H1'), 3.80-
3.85 (m, 1H, H2), 4.40 (d, J = 5.2 Hz, 1H, H3), 7.25-7.38 (m, 15H, Ar). 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-4-C-octyl-5-O-trityl-D-ribitol 
(74c). Treatment of 73 (480 mg, 0.87 mmol) with octyl-MgBr (2 M/THF; 7.5 mL, 15 
mmol) by Procedure C gave 74c (350 mg, 60%) as a clear oil: 1H NMR (CDCl3) δ 0.08 
(s, 6H, SiMe2), 0.81 (s, 9H, Si-C-Me3), 0.89 (t, J= 6.6 Hz, Me, C8a), 1.28-1.30 (m, 12H, 
C2a-C7a), 1.38 (s, 3H, Me), 1.42 (s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 3.05 (d, J = 8.9 
Hz, 1H, H5), 3.21 (d, J = 8.9 Hz, 1H, H5'), 3.26 (dd, J = 3.8, 11.0 Hz, 1H, H1), 3.70 (dd, 
J = 3.9, 7.6 Hz, 1H, H1'), 3.80-3.85 (m, 1H, H2), 4.40 (d, J = 5.2 Hz, 1H, H3), 7.25-7.38 
(m, 15H, Ar). 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-5-O-trityl-4-C-vinyl-D-ribitol 
(74d). Treatment of 73 (120 mg, 0.21 mmol) with vinyl-MgBr (1 M/THF; 0.63 mL, 0.63 
mmol) by Procedure C gave 74d (70 mg, 55%) as a clear oil: 1H NMR (CDCl3) δ 0.08 (s, 
6H, SiMe2), 0.81 (s, 9H, Si-C-Me3), 1.35 (s, 3H, Me), 1.37 (s, 3H, Me), 2.92 (d, J = 9.0 
Hz, 1H, H5), 3.12  (d, J = 9.0 Hz, 1H, H5'), 3.42 (dd, J = 4.5, 10.7 Hz, 1H, H1), 3.80 (dd, 
J= 8.5, 10.7 Hz, 1H, H1'), 4.00-4.13 (m, 1H, H2), 4.69 (d, J = 6.1 Hz, 1H, H3), 5.16 (dd, 
J= 1.7, 10.9 Hz, 1H, CH=CHH), 5.40 (dd, J = 1.8, 17.4 Hz, 1H, CH=CHH ), 6.20 (dd, J 
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= 10.9, 17.4 Hz, 1H, CH=CHH), 7.25-7.38 (m, 15H, Ar); 13C NMR δ -5.40 (SiMe2), 
21.02 & 25.29 (CMe2), 25.77 (Si-C-Me3), 31.58 (Si-C-Me3), 60.47 (C-Ph3), 61.98 (C1), 
69.13 (C5), 74.87 (C4), 78.15 (C2), 78.45 (C3), 107.87 (CH=CHH), 114.84 (C-Me2), 
126.91 & 127.71 & 128.87 & 143.40 (Ar), 138.71 (CH=CHH), 146.89; HRMS calcd for  
C35H46O5NaSi+  [M+Na]+ 597.3007, found 597.3006. 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-4-C-4-methoxyphenyl-5-O-
trityl-D-ribitol (74e), Treatment of 73 (165 mg, 0.30 mmol) with methoxyphenyl-MgBr 
(1 M/THF; 0.89 mL, 0.89 mmol) by Procedure C gave 74e (190 mg, 96%) as a clear 
oil:1H NMR (CDCl3) δ 0.08 (s, 6H, SiMe2), 0.81 (s, 9H, Si-C-Me3), 1.35 (s, 3H, Me), 
1.37 (s, 3H, Me), 3.01 (d, J = 9.1 Hz, 1H, H5), 3.15 (d, J = 9.1 Hz, 1H, H5'), 3.41 (dd, J = 
4.5, 10.8 Hz, 1H, H1), 3.80 (s, 3H, CH3O), 3.85 (dd, J = 4.5, 10.8 Hz, 1H, H1'), 4.19-4.22 
(m, 1H, H2), 5.05 (d, J = 6.4 Hz, 1H, H3), 6.85 (d, J = 6.9 Hz, 2H, Ar), 7.61 (d, J = 8.9 
Hz, 2H, Ar), 7.25-7.38 (m, 15H, Ar); HRMS calcd for C40H50O6NaSi+  [M+Na]+ 
677.3269, found 677.3267. 
2,3-O-Isopropylidene-4-C-methyl-5-O-trityl-D-ribitol (75a). Procedure D. TBAF 
(1 M/THF; 0.5 mL, 0.5 mmol) was added to a stirred solution of 74a (183 mg, 0.32 mmol) 
in THF (6 mL) at 0 °C (ice-bath). After 30 min, the volatiles were evaporated and the 
resulting residue was washed with NaHCO3/H2O and extracted with EtOAc. The organic 
layer was then dried over Mg2SO4 and evaporated to give crude residue which was 
column chromatographed (80 → 70% hexane/EtOAc) to give 75a (100 mg, 68%): 1H 
NMR (CDCl3) δ 1.35 (s, 3H, CH3, C1a), 1.40 (s, 3H, Me), 1.49 (s, 3H, Me), 3.05 (d, J = 
9.0 Hz, 1H, H5), 3.32  (d, J = 9.0 Hz, 1H, H5'), 3.58 (dd, J = 5.2, 12.0 Hz, 1H, H1), 3.75 
(dd, J= 5.5, 12 Hz, 1H, H1'), 4.10- 4.20 (m,1H, H2), 4.30 (d, J = 6.2 Hz, 1H, H3), 7.25-
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7.38 (m, 15H, Ar); 13C NMR (CDCl3) δ 14.21 (C1a), 25.17 & 27.28 (CMe2), 60.42 (C5), 
61.43 (C1), 67.95 (C-Ph3), 68.38 (C4), 77.61 (C2), 79.10 (C3), 107.67 (CMe2), 127.27 & 
127.97 & 128.62 & 143.43 (Ar).  
2,3-O-Isopropylidene-4-C-hexyl-5-O-trityl-D-ribitol (75b). Treatment of  74b (280 
mg, 0.44 mmol) with TBAF by Procedure D gave 75b (145 mg, 87%) as an viscous oil: 
1H NMR (CDCl3) δ 0.85 (t, J= 6.6 Hz, Me, C6a), 1.30-1.40 (m, 8H, C2a-C5a), 1.25 (s, 
3H, Me), 1.40 (s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 2.91 (d, J = 9.3 Hz, 1H, H5), 3.20 (d, 
J = 9.3 Hz, 1H, H5'), 3.30 (dd, J = 5.0, 12.2 Hz, 1H, H1), 3.40 (dd, J = 5.0, 12.0 Hz, 1H, 
H1'), 3.79-3.82 (q, J = 5.8 Hz, 1H, H2), 4.15 (d, J = 5.8 Hz, 1H, H3), 7.25-7.38 (m, 15 
Hz, Ar); 13C NMR (CDCl3) δ 14.14 (C6a), 22.66, 23.54, 25.45, 27.57 (C2a-C5a), 29.74 & 
31.83 (CMe2), 36.05 (C1a), 61.71 (C5), 65.39 (C1), 72.06 (C-Ph3),  77.55 (C4), 78.99 
(C2), 86.92 (C3), 107.21 (CMe2), 127.31 & 127.96 & 128.65 & 145.26 (Ar); HRMS 
calcd for C33H42O5Na+  [M+Na]+ 541.2924, found 541.2924.  
2,3-O-Isopropylidene-4-C-octyl-5-O-trityl-D-ribitol (75c). Treatment of  74c 
(350 mg, 0.52 mmol) with TBAF by Procedure D gave 75c (200 mg, 84%) as an viscous 
oil. 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, CH3, C8a), 1.20 (s, 12H, C2a-C7a), 1.29 (s, 
3H, Me), 1.40 (s, Me), 1.50-1.60 (m, 2H, C1a), 2.95 (d, J= 9.4 Hz, 1H, H5), 3.25 (d, J= 
9.3 Hz, 1H, H5'), 3.35 (dd, J= 4.92, 12.2 Hz, 1H, H1), 3.45 ( dd, J= 5.4, 12.2 Hz, 1H, 
H1'), 3.80 (m, 1H, H2), 4.10 ( d, J = 5.8 Hz, 1H, H3), 7.25- 7.38 (m, 15H, Ar); 13C NMR 
(CDCl3) δ 14.11 (C8a), 22.68, 23.09, 25.43, 27.55, 28.42, 29.24 (C2a-C7a), 29.56 & 
30.08 (CMe2), 36.06 (C1a), 61.89 (C5), 64.24 (C1), 66.95 (C-Ph3), 74.36 (C4), 77.61 
(C2), 79.18 (C3), 107.20 (CMe2), 126.91 & 127.71 & 128.87 & 143.40 (Ar); HRMS 
calcd for  C35H46O5Na+  [M+Na]+ 569.3237, found 569.3237.  
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2,3-O-Isopropylidene-4-C-vinyl-5-O-trityl-D-ribitol (75d). Treatment of 74d (200 
mg, 0.34 mmol) with TBAF by Procedure D gave 75d (124mg, 77%) as a viscous oil: 1H 
NMR (CDCl3) δ 1.35 (s, 3H, Me), 1.37 (s, 3H, Me), 3.38 (d, J = 11.2 Hz, 1H, H5), 3.54 
(d, J = 11.2 Hz, 1H, H5'), 3.58 (dd, J = 5.1, 11.3 Hz, 1H, H1), 3.90 (d, J = 8.6, 11.3 Hz, 
1H, H1'), 4.25-4.30 (m, 1H, H2), 4.32 (d, J = 6.5 Hz, 1H, H3), 5.20 (dd, J = 1.2, 11.0 Hz, 
1H, CH=CHH), 5.40 (dd, J = 1.5, 17.6 Hz, 1H, CH=CHH), 6.20 (dd, J = 11.0, 17.5 Hz, 
1H, CH=CHH), 7.25-7.38 (m, 15H, Ar). 13C NMR (CDCl3) δ 24.65 & 27.07 (C-Me2), 
60.29 (CPh3), 60.62 (C1), 68.07 (C5), 77.90 (C2), 78.10 (C4), 82.01 (C3), 115.48 (C-
Me2), 116.03 (CH=CHH), 126.82 & 127.65 & 128.75 & 143.28 (Ar), 146.88 
(CH=CHH).  
2,3-O-Isopropylidene-4-C-4-methoxyphenyl-5-O-trityl-D-ribitol (75e). Treatment 
of 74e (190 mg, 0.29 mmol) with TBAF by Procedure D gave 75e (92 mg, 59%) as a 
viscous oil: 1H NMR (CDCl3) δ 1.35 (s, 3H, Me), 1.37 (s, 3H, Me), 3.01 (dd, J = 6.0, 
11.7 Hz, 1H, H1), 3.03 (d, J = 9.0 Hz, 1H, H5), 3.23 (dd, J = 6.0, 11.7 Hz, 1H, H1'), 3.45 
(d, J = 9.0 Hz, 1H, H5'), 3.72 (s, 3H, CH3O), 4.19-4.22 (m, 1H, H2), 4.75 (d, J = 6.6 Hz, 
1H, H3), 6.85 (d, J = 6.9 Hz, 2H, Ar), 7.61 (d, J = 8.9 Hz, 2H, Ar), 7.25-7.38 (m, 15H, 
Ar); 13C NMR δ 24.58 & 27.02 (C-Me2), 55.19 (CH3O), 60.04 (CPh3), 61.28 (C1),  69.73 
(C5), 78.08 (C2), 79.05 (C3), 82.02 (C4), 113.48 (C-Me2), 127.25, 127.37, 127.92, 
159.10 (Ar), 128.57 & 129.68 & 132.91 & 146.88 (Ar). 
2,3-O-Isopropylidene-4-C-methyl-5-O-trityl-D-ribono-1,4-lactone (76a). 
Procedure E. N-methylmorpholine N-oxide (NMO; 50 mg, 0.42 mmol), 
tetrapropylammonium perrenthenate (TPAP; 1 mg, 0.002 mmol) and 4 Å molecular 
sieves (100 mg) were added to a stirred solution of 75a (51 mg, 0.11 mmol) in CH2Cl2 
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(3.7 mL) at ambient temperature under N2 atmosphere. After 6 h, the reaction mixture 
was filtered off and the filtrate was dried over MgSO4 and evaporated. The residue was 
purified by flash column chromatography (75 → 50% hexane/EtOAc) to give 76a (40 
mg, 80%): 1H NMR (CDCl3) δ 1.30 (s, 3H, C1a), 1.35 (s, 3H, Me), 1.40 (s, 3H, Me), 2.91 
(d, J = 10.2 Hz, 1H, H5), 3.50 (d, J = 10.2 Hz, H1, H5'), 4.20 (d, J= 5.6 Hz, 1H, H2), 
5.01 (d, J = 5.6 Hz, 1H, H3), 7.25-7.38 (m, 15 Hz, Ar). 13C NMR (CDCl3) δ 16.40 (C1a) 
25.90 & 26.78 (C-Me2), 66.65 (CPh3), 67.63 (C5), 77.70 (C2), 79.77 (C3), 88.56 (C4), 
126.07 (C-Me2), 127.46 & 128.25 & 128.67 & 146.87 (Ar), 172.07 (C1). 
2,3-O-Isopropylidene-4-C-hexyl-5-O-trityl-D-ribono-1,4-lactone (76b). Treatment 
of 75b (37 mg, 0.09 mmol) with NMO/TPAP by Procedure E gave 76b (35 mg, 94%): 1H 
NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, 3H, C6a), 1.19-1.21 (m, 8H, C2a-C5a), 1.24 (s, 3H, 
Me), 1.40 (s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 2.85 (d, J =10.2 Hz, 1H, H5), 3.51 (d, J = 
10.2 Hz, 1H, H5'), 4.10 (d, J= 5.6 Hz, 1H, H2), 5.01 (d, J= 5.6 Hz, 1H, H3), 7.25-7.38 
(m, 15 Hz); 13C NMR (CDCl3) δ 13.98 (C6a), 23.33 & 26.76 (C-Me2), 29.69, 31.38, 
29.42, 29.52 (C2a-C5a), 31.60 (C1a), 66.15 (CPh3),  66.29 (C5), 77.21 (C2), 80.11 (C3), 
88.25 (C4), 112.92 (C-Me2), 127.36 & 128.32 & 128.67 & 142.85 (Ar), 174.41 (C1).  
2,3-O-Isopropylidene-4-C-octyl-5-O-trityl-D-ribono-1,4-lactone (76c). Treatment 
of 75c (12 mg, 0.02 mmol) with NMO/TPAP by Procedure E gave 76c (8 mg, 95%): 1H 
NMR (CDCl3) δ 0.80-0.84 (m, Me, C8a), 1.10-1.20 (s, 12H, C2a-C7a), 1.25 (s, Me), 1.40 
(s, Me), 1.50-1.60 (m, C1a), 2.90 (d, J = 10.1 Hz, 1H, H5), 3.55 (d, J = 10.2 Hz, 1H, 
H5'), 4.10 (d, J = 5.6 Hz, 1H, H2), 5.01 (d, J = 5.6 Hz, 1H, H3), 7.25-7.38 (m, 15H, Ar); 
13C NMR (CDCl3) δ 13.2 (C8a), 21.79 & 22.61 (CMe2), 25.05, 25.07, 28.23, 28.39, 
29.20, 29.25 (C2-C7), 30.98 (C1a), 64.91 (CPh3), 65.06 (C5), 65.44 (C2), 79.25 (C3), 
89 
 
87.41 (C4), 112.07 (CMe2), 126.56 & 127.30 & 127.67 & 142.09 (Ar), 170.21 (C1); MS 
(ESI+) m/z 560 (M+NH4). 
Note When 76c is left in solution overnight, a second minor product 76'c appeared to 
be formed with a ratio of 76'c:76c (1:3); the ribosyl peaks for the 76c’ product were as 
followed: 1H NMR (CDCl3) δ 3.75 (d, J = 11.6 Hz, 1H, H5'), 3.91 (d, J = 11.6 Hz, 1H, 
H5), ), 4.60 (d, J = 5.6 Hz, 1H, H2), 4.90 (d, J = 5.6 Hz, 1H, H3); MS (ESI+) m/z 605 
(M+2Na+). 
2,3-O-Isopropylidene-5-O-trityl-4-C-vinyl-D-ribono-1,4-lactone (76d). Treatment 
of 75d (100 mg, 0.21 mmol) with NMO/TPAP by Procedure E gave 76d (90 mg, 95%): 
1H NMR (CDCl3) δ 1.22 (s, 3H, Me), 1.26 (s, 3H, Me), 2.91 (d, J = 10.2 Hz, 1H, H5), 
3.50 (d, J = 10.3 Hz, H1, H5'), 4.20 (d, J= 5.6 Hz, 1H, H2), 5.00 (d, J = 5.6 Hz, 1H, H3), 
5.21 (d, J = 11.2 Hz, 1H, CH=CHH), 5.34 (d, J = 17.4 Hz, 1H, CHH ), 5.61 (dd, J = 11.2, 
17.4 Hz, CH=CHH), 7.25-7.38 (m, 15 H). 13C NMR (CDCl3) δ 25.92 & 26.64 (CMe2), 
53.50 (CPh3), 65.50 (C5), 80.01 (C2), 82.03 (C3), 88.87 (C4), 112.03 (CH=CHH),  
118.50 (C-Me2), 127.29 & 127.95 & 129.69 & 145.01 (Ar), 146.85 (CH=CHH), 174.14 
(C1); HRMS (TOF) m/z calcd for  C29H28O5+  [M+Na]+ 479.1829, found 479.1829. 
2,3-O-Isopropylidene-4-C-4-methoxyphenyl-5-O-trityl-D-ribono-1,4-lactone 
(76e). Treatment of 75e (90 mg, 0.16 mmol) with NMO/TPAP by Procedure E gave 76e 
(73 mg, 82%): 1H NMR (CDCl3) δ 1.22 (s, 3H, Me), 1.25 (s, 3H, Me), 3.25 (d, J = 10.5 
Hz, 1H, H5'), 3.35 (d, J = 10.5 Hz, 1H, H5), 3.80 (s, 3H, CH3O), 4.48 (d, J = 5.5 Hz, 1H, 
H2), 5.20 (d, J = 5.5 Hz, 1H, H3), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.7 Hz, 2H, 
Ar), 7.25- 7.38 (m, 15H, Ar); 13C NMR (CDCl3) δ 25.92 & 26.64 (CMe2), 55.18 (CH3O), 
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62.94 (CPh3), 68.79 (C5), 80.77 (C2), 88.53 (C3), 88.87 (C4), 113.60 (CMe2), 126.9 & 
127.25 &128.75 & 159.10, (Ar), 128.57 & 129.68 & 132.91 & 146.40 (Ar), 174.14 (C1). 
 Attempts to synthesize 4-C-octyl-D-ribono-1,4-hemiacetal (81c) by the Swern 
oxidation of 4-C-alkyl-D-ribitol (75c): To a solution of oxalyl chloride (0.01 mg, 
0.0001mmol, 0.013 mL) and DMSO (0.02 mg, 0.0002 mmol, 0.02 mL) in dry CH2Cl2 
(0.14 mL) at -60 oC for 15 min, was added dropwise the solution of 75c (70 mg, 0.13 
mmol) in CH2Cl2 (0.14 mL). The reaction was stirred for 15 min and dry triethylamine 
(0.06 mg, 0.006 mmol, 95 µL) was over a period of 10 min at -60 oC. The mixture was 
extracted with H2O and CH2Cl2. The organic layer was washed with brine, dried over 
MgSO4, and evaporated. Purification on silica gel column (hexane/EtOAc, 8:2) gave a 
mixture of products (≈10 mg) with distinguishable sugar peaks.  
2,3-O-Isopropylidene-4-C-methyl-D-ribono-1,4-lactone (84a). Procedure F. TFA 
(0.22 mL) and CH2Cl2 (4 mL) were added to a stirred solution of 76a (40 mg, 0.009 
mmol) at ambient temperature for 5 h. The volatiles were evaporated and residue co-
evaporated with toluene. The oily residue was partitioned between aqueous NaHCO3 and 
CH2Cl2. The separated organic layer was washed with brine, dried MgSO4, and 
evaporated. Purification on silica gel column (hexane/EtOAc, 8:2) gave 84a (12 mg, 
66%): 1H NMR(CDCl3) δ 1.32 (s, 3H, C1a), 1.35 (s, 3H, Me), 1.42 (s, 3H, Me), 3.60 (d, J 
= 11.6 Hz, 1H, H5), 3.71 (d, J = 11.6 Hz, H1, H5'), 4.55 (d, J= 5.6 Hz, 1H, H2), 4.90 (d, 
J = 5.6 Hz, 1H, H3). 13C NMR (CDCl3) δ 16.42 (C1a), 25.81 & 26.76 (CMe2), 67.61(C5), 
77.82 (C2), 80.01 (C3), 86.35 (C4), 113.02 (CMe2), 174.46 (CO);  HRMS (TOF) m/z 
calcd for  C9H14O5Na + [M+Na]+ 225.0733, found 225.0734. 
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2,3-O-Isopropylidene-4-C-hexyl-D-ribono-1,4-lactone (84b) and 2,3-O-
Isopropylidene-4-C-hexyl-D-ribono-1,5-lactone (88b). Treatment of 76b (30 mg, 0.058 
mmol) with TFA by Procedure F (flash column chromatography; 80% hexane/EtOAc) 
gave 84b (12 mg, 80%): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, CH3, C6a), 1.19-1.21 (m, 
8 H, C2a-C5a), 1.41 (s, 3H, Me), 1.50 (s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 3.75 (d, J= 
11.8 Hz, 1H, H5), 3.85 (d, J = 11.4 Hz, 1H, H5'), 4.65 (d, J = 5.6 Hz, 1H, H2), 4.96 (d, J 
= 5.6 Hz, 1H, H3). 13C NMR (CDCl3) δ 13.97 (C6a), 23.43 & 25.79 (CMe2), 29.41, 
29.56, 29.71, 31.14 (C2a-C5a), 31.91 (C1a), 77.20 (C5), 71.89 (C2), 80.63 (C3), 89.73 
(C4), 112.85 (CMe2), 172.45 (CO); HRMS (TOF) m/z calcd for  C14H24O5Na + [M+Na]+ 
295.1516, found 295.1516.                                                                                                                            
Note: When the reaction of 76b with TFA was kept overnight, the mixture of 84b and 
its D-ribono-1,5-lactone (88b) was isolated after column chromatography (84b/88b, 1:1, 
12 mg, 80%). The ribosyl peaks for the 88b product were as followed:  1H NMR (CDCl3) 
δ 3.95 (d, J= 12.7 Hz, 1H, H5), 4.20 (d, J= 12.7 Hz, 1H, H5'), 4.22 (d, J= 2.4 Hz, 1H, 
H2), 4.37 (dd, J= 0.9, 2.5 Hz, 1H, H3); 13C NMR (CDCl3) δ 14.08 (C6a), 22.67 & 23.54 
(CMe2), 26.78, 27.05, 31.6, 31.59 (C2a-C5a), 37.07 (C1a), 65.83 (C5), 69.06 (C2), 79.76 
(C3), 87.97 (C4), 128.54 (CMe2), 142.95 (C1).  
2,3-O-Isopropylidene-4-C-octyl-D-ribono-1,4-lactone (84c). Treatment of  76c (35 
mg, 0.064 mmol) with TFA by Procedure F gave 84c (16 mg, 75%):  1H NMR (CDCl3) δ 
0.80 (t, J= 6.6 Hz, CH3, C8a), 1.30-1.32 (m, 12H, C2a-C7a), 1.40 (s, 3H, Me), 1.50 (s, 
3H, Me), 1.50-1.60 (m, 2H, C1a), 3.75 (d, J = 11.6 Hz, 1H, H5), 3.85 (d, J = 11.6 Hz, 
1H, H5'), 4.65 (d, J = 5.6 Hz, 1H, H2), 4.95 (d, J = 5.6 Hz, 1H, H3); 13C NMR (CDCl3) δ 
14.08 (CH3, C8a), 22.63 & 23.46 (CMe2),  25.81, 26.74, 29.12, 29.24, 30.04, 31.14  (C2a-
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C7a), 31.82 (C1a), 65.89 (C5), 77.31 (C2), 79.74 (C3), 88.53 (C4), 112.07 (CMe2), 
174.57 (C1); HRMS (TOF) m/z calcd for C16H28O5Na+  [M+Na]+ 323.1829, found: 
323.1915. 
2,3-O-Isopropylidene-4-C-vinyl-D-ribono-1,4-lactone (84d). Treatment of 76d (30 
mg, 0.065 mmol) with TFA by Procedure F (flash column chromatography; 80% 
hexane/EtOAc) gave somehow an unstable product 84d (5 mg, 35%): 1H NMR (CDCl3) δ 
1.22 (s, 3H, Me), 1.26 (s, 3H, Me), 3.61 (d, J = 11.7 Hz, 1H, H5), 3.65 (d, J = 11.8 Hz, 
1H, H5'), 4.60 (d, J = 5.6 Hz, 1H , H2), 4.82 (d, J = 5.6 Hz, 1H, H3), 5.24 (d, J = 11.3 
Hz, 1H, CH=CHH), 5.34 (d, J =17.5 Hz, 1H, C=CHH), 5.71 (dd, J = 11.2, 17.5 Hz, 
CH=CHH); 13C NMR (CDCl3) δ 25.87, 26.70 (CMe2), 66.37 (C5), 76.70 (C2), 80.01 
(C3), 87.95 (C4), 113.29 (CMe2), 118.21 (CH=CH2), 130.53 (CH=CH2), 174.06 (CO); 
HRMS (TOF) m/z calcd for  C10H14O5Na+  [M+Na]+ 237.0733, found 237.0733. 
2,3-O-Isopropylidene-4-C-4-methoxyphenyl-D-ribono-1,4-lactone (84e). 
Treatment of 76e (70 mg, 0.13 mmol) with TFA by Procedure F (flash column 
chromatography; 80% hexane/EtOAc) gave somehow an unstable product 84d (20 mg, 
60%): 1H NMR (CDCl3) δ 1.22 (s, 3H, Me), 1.25 (s, 3H, Me), 3.80 (s, 3H, CH3O), 3.85 
(d, J = 12.3 Hz, 1H, H5), 3.95 (d, J = 12.5 Hz, 1H, H5'), 4.95 (d, J = 5.4 Hz, 1H, H2), 
5.15 (d, J = 5.3 Hz, 1H, H3), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 Hz, 2H, Ar); 
13C NMR (CDCl3) δ 25.83 & 26.65 (CMe2), 55.25 (CH3O), 68.50 (C5), 77.41 (C2), 80.57 
(C3), 90.12 (C4), 112.93 (CMe2), 113.76, 126.17, 126.89, 159.33 (Ar); 174.86 (C1); 
HRMS (TOF) m/z calcd for  C15H18O6Na+  [M+Na]+ 317.0996, found 317.0982. 
2,3-O-Isopropylidene-5-O-mesyl-4-C-methyl-D-ribono-1,4-lactone (85a). 
Treatment of 75a (20 mg, 0.09 mmol) with MsCl by Procedure A (column 
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chromatography; hexane/EtOAc, 6:4) gave 76a (17 mg, 63%): 1H NMR (CDCl3) δ 1.32 
(s, 3H, C1a), 1.35 (s, 3H, Me), 1.42 (s, 3H, Me),  2.99 (s, 3H, Ms), 4.15 (d, J = 11.0 Hz, 
1H, H5), 4.25 (d, J = 10.9 Hz, 1H, H5'), 4.60 (d, J = 5.7 Hz, 1H, H2), 4.85  (d, J = 5.7 
Hz, 1H, H3). 
2,3-O-Isopropylidene-4-C-hexyl-5,O-mesyl-D-ribono-1,4-lactone (85b). Treatment 
of  84b (22 mg, 0.08 mmol) with MsCl by Procedure A (column chromatography; 
hexane/EtOAc, 7:3) gave 85b  (14 mg, 50%): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, 3H, 
C6a), 1.20-1.28 (m, 8H, C2a-C5a), 1.33 (s, 3H, Me), 1.41 ( s, 3H, Me), 1.50-1.60 (m, 2H, 
C1a),  2.99 (s, 3H, Ms), 4.20 (d, J = 11.0 Hz, 1H, H5), 4.32 (d, J = 11.0 Hz, 1H, H5'), 
4.60 (d, J = 5.7 Hz, 1H, H2), 4.88  (d, J = 5.7 Hz, 1H, H3); 13C NMR (CDCl3) δ 14.03 
(CH3, C6a), 22.46 & 23.37 (CMe2), 25.78, 26.69, 29.55, 31.38 (C2a-C5a), 31.45 (C1a), 
45.20 (Ms), 71.80 (C5), 77.91 (C3), 85.77 (C2), 113.79 (C4), 117.85 (CMe2), 173.21 
(C1). 
2,3-O-Isopropylidene-5-O-mesyl-4-C-octyl-D-ribono-1,4-lactone (85c). Treatment 
of  84c (32 mg, 0.1 mmol) with MsCl by Procedure A (column chromatography; 
hexane/EtOAc, 6:4) gave 85c (14 mg, 50%): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, Me, 
C8a), 1.20-1.28 (m, 12H, C2a-C7a), 1.35 (s, 3H, Me), 1.41 (s, 3H, Me), 1.50-1.60 (m, 
2H, C1a), 3.0 (s, 3H, Ms), 4.20 (d, J = 10.9 Hz, 1H, H5), 4.32 (d, J = 10.9 Hz, 1H, H5'), 
4.60 (d, J = 5.6 Hz, 1H, H2), 4.84 (d, J = 5.6 Hz, 1H, H3); 13C NMR (CDCl3) δ 14.08 
(CH3, C8a), 22.63 & 23.46 (CMe2), 25.81, 26.74, 29.12, 29.24, 30.04, 30.52 (C2a-C7a), 
31.14 (C1a), 44.50 (Ms), 71.76 (C5), 77.31 (C3), 78.91 (C2), 113.76 (C4), 117.92 
(CMe2), 171.01 (C1).  
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2,3-O-Isopropylidene-5,O-mesyl-4-C-4-methoxyphenyl-D-ribono-1,4-lactone 
(85e). Treatment of 84e (24 mg, 0.08 mmol) with MsCl by Procedure A (column 
chromatography; hexane/EtOAc, 6:4) gave 85e (25 mg, 83%): 1H NMR (CDCl3) δ 1.35 
(s, 3H, Me), 1.41 (s, 3H, Me), 3.0 (s, 3H, Ms), 3.80 (s, 3H, CH3O), 4.20 (d, J = 11.2 Hz, 
1H, H5), 4.55 (d, J = 11.2 Hz, 1H, H5'), 5.01 (d, J = 5.5 Hz, 1H, H2), 5.15 (d, J = 5.5 Hz, 
1H, H3), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 Hz, 2H, Ar); 13C NMR (CDCl3) δ 
25.90 & 26.58 (CMe2), 44.10 (Ms), 55.33 (CH3O), 73.26 (C5), 77.35 (C2), 79.71 (C3), 
87.04 (C4), 113.79 (CMe2), 114.10, 124.91, 127.00, 159.95 (Ar); 173.01 (C1).  
2,3-O-Isopropylidene-4-C-hexyl-5-O-trityl-D-ribofuranose (86b). LiEt3BH 
(1M/THF, 0.18 mL, 0.18 mmol) was added dropwise to a solution of 84b (37 mg, 0.07 
mmol) in CH2Cl2 (0.5 mL). The mixture was stirred for 30 min at 0 oC (ice-bath) under 
N2 atmosphere. The reaction was quenched with MeOH, the volatiles were then 
evaporated. The residue was partitioned between CH2Cl2 and NaHCO3, washed with 
brine and dried with anhydrous MgSO4. The resulting oil was column chromatographed 
(75:15, hexane: ethyl acetate) to give a mixture of anomers α/β 86b (α: β; 1:3; 20 mg, 
54%): The major anomer had: 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, 3H, C6a), 1.20-
1.28 (m, 8H, C2a-C5a), 1.33 (s, 3H, Me), 1.41 (s, 3H, Me), 1.50-1.60 (m, 2H, C1a), 3.16 
(d, J = 10.08 Hz, 1H, H5), 3.32 (d, J = 10.08 Hz, 1H, H5'), 3.74 (d, J = 8.8 Hz, OH), 4.50 
(d, J = 6.0 Hz, 1H, H3), 4.75 (d, J = 6.0 Hz, 1H, H2), 5.15 (d, J = 8.4 Hz, 1H, H1). 7.25- 
7.38 (m, 15H, Ar); the minor anomer had: 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, 3H, 
C6a), 1.20-1.28 (m, 8H, C2a-C5a), 1.33 (s, 3H, Me), 1.41 (s, 3H, Me), 1.50-1.60 (m, 2H, 
C1a), 2.94 (d, J = 9.9 Hz, 1H, H5), 3.25 (d, J = 9.9 Hz, 1H, H5'), 3.86 (d, J = 11.5 Hz, 
OH), 4.20 (d, J = 6.1 Hz, 1H, H3), 4.62 (dd, J = 4.2, 6.1 Hz, 1H, H2), 5.61 (dd, J = 4.2, 
95 
 
11.5 Hz, 1H, H1), 7.25-7.38 (m, 15H, Ar). α/β-anomers mixture had: 13C NMR (CDCl3) 
δ 14.01, 23.61 (C6a, α & β anomers), 23.94 (C6a), 24.57 & 24.98 (CMe2), 25.99, 26.22, 
29.65, 31.51 (C2a-C5a), 31.83 (C1a), 67.33 & 68.18 (C5), 80.01 & 82.78 (C2), 83.09 & 
83.82 (C3), 88.05 & 88.12 (C4), 96.55 & 102.85(C1), 112.06 & 112.32 (CMe2), 126.56, 
127.30, 127.67, 142.09 (Ar), 139.0 & 143.1 (CO), 156.08 & 158.03 (CO), 174.81 (C1).  
2,3-O-Isopropylidene-4-C-octyl-D-ribofuranose (86c). Treatment of 84c (11 mg, 
0.03 mmol) with LiEt3BH, as described for 86b gave a mixture of α/β-anomers 86c (α:β; 
1:1; 7 mg, 63%) 1H NMR (CDCl3) δ  0.80-0.82 (m, 2 x C8a), 1.20-1.28 (m, 24H, 6 x 2 x 
CH2, C2a-C7a), 1.33 (s, 6H, 2 x Me), 1.41 (s, 6H, 2 x Me), 1.50-1.60 (m, 4H, 2 x C1a),  
3.55 (d, J = 11.8 Hz, 2H, H5), 3.94 (d, J = 11.8 Hz, 2H, H5'), 3.96 (d, J = 7.9 Hz, 1H, 
H3, α-anomer),  4.10 (dd, J = 4.2, 7.9 Hz, 1H, H2, α-anomer), 4.28 (m, 1H, H2, β-
anomer), 4.41 (d, J = 5.0 Hz, 1H, H3, β-anomer), 4.81 (s, 1H, H1, β-anomer), 5.09 (d, J= 
4.1 Hz, 1H, H1, α-anomer). 
S-(2,3-O-Isopropylidene-4-C-hexyl-D-ribono-1,4-lactone-5-yl)-N-tert-
butoxycarbonyl-L-homocysteine tert-butyl ester (89b). Procedure G. LDA (2M/THF 
and heptanes, 40 µl, 0.08 mmol) was added slowly to a stirred solution of protected L-
homocysteine 49 (27 mg, 0.093 mmol) (prepared by Procedure B, step a) in anhydrous 
DMF 1.5 ml under Ar atmosphere at 0 oC (ice bath). After 30 min, solution 85b (11 mg, 
0.031 mmol) in DMF(2 mL) was added by a syringe and the mixture was left stirring for 
15 min at 0 oC then at room temperature for 24 hours. The TLC shows 5 different spots. 
The significant ones were the ones for disulfide (Rf = 0.55), the thiol (Rf = 0.65), the 
desired product at Rf = 0.50 and a byproduct at Rf = 0.30. The reaction was quenched 
with NH4Cl and volatiles were evaporated on high vaccum. The residue was partitioned 
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between ethyl acetate and NaHCO3, washed with brine and dried with anhydrous MgSO4. 
The resulting oil was column chromatographed (8:2, hexane: ethyl acetate) to give 89b 
(18 mg, 65%): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, 3H, C6a), 1.20-1.28 (m, 2 x 4 CH2, 
C2a-C5a), 1.31 (s, 3H, Me), 1.39 &1.41 (2 x s, 18H), 1.42 (s, 3H, Me), 1.50-1.60 (m, 2H, 
C1a),  2.99 (s, 3H), 1.80 (m, 1H, H7), 1.90 (m, 1H, H7'), 2.50 (m, 2H, H6 and H6'), 2.72 
(d, J = 14.68 Hz, 1H, H5), 2.80 (d, J = 14.72 Hz, 1H, H5'), 4.20-4.25 (m, 1H, C8), 4.40 
(d, J = 5.92 Hz, 1H, H3), 5.00 (d, 1H, NH), 5.10 ( d, J = 5.88 Hz, 1H, H2). 13C NMR 
(CDCl3) δ 14.01 (C6a), 22.5 & 22.7 (CMe2), 23.45, 25.66, 26.56, 30.67 (C2a-C5a), 28.08 
(t-Bu), 28.32 (t-Bu), 34.34 (C1a), 39.86 (C5), 77.0 (C2), 77.20 (C3), 80.59 (CO), 82.41 
(CO), 88.98 (C4), 113.30 (CMe2), 139.0 (CO), 156 (CO), 174 (C1). HRMS calcd for 
C27H48NO8S+ [M+H]+ 546.3095, found 546.3104. 
S-(2,3-O-Isopropylidene-4-C-octyl-D-ribono-1,4-lactone-5-yl)-N-tert-
butoxycarbonyl-L-homocysteine tert-butyl ester (89c). Treatment of 85c (24 mg, 0.063 
mmol) with homocysteinate lithium salt as described by procedure G gave a mixture of 
Hcy and 89c that couldn’t be separated on column since they have the same Rf = 0.55 
(5:1, 60 mg): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, Me, C8a), 1.20-1.25 (m, 12H, C2a-
C7a), 1.21 (s, 3H, Me), 1.40 (s, 3H, Me), 1.39 &1.41 (2 x s, 90H), 1.50-1.60 (m, 2H, 
C1a), 1.85-1.89 (m, 6H, H7), 1.9-2.0 (m, 6H, H7'), 2.68-2.71 (m, 10H, H6 and H6'), 2.80-
2.83 (m, H5, H5', 2H), 4.20-4.26 (m, C8, 9H), 4.40 (d, J = 5.92 Hz, 1H, H3), 5.10 (d, 1H, 
NH), 5.15 (d, J = 5.88 Hz, 1H, H2).  
S-(2,3-O-Isopropylidene-4-C-4-methoxyphenyl-D-ribono-1,4-lactone-5-yl)-N-tert-
butoxycarbonyl-L-homocysteine tert-butyl ester (89e). Treatment of 85e (22 mg, 0.07 
mmol) with homocysteinate lithium salt as described by procedure G gave a mixture of 
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Hcy and 89e (20 mg, 48%): 1H NMR (CDCl3) δ 1.35 (s, 3H, Me), 1.41 (s, 3H, Me), 1.39 
&1.41 (2x s, 18H), 1.80 (m, 1H, H7), 1.90 (m, 1H, H7'), 2.50 (m, 2H, H6 and H6'), 2.85 
(d, J = 14.8 Hz, 1H, H5), 3.20 (d, J = 15.1 Hz, 1H, H5'), 3.80 (s, 3H, CH3O), 4.20-4.25 
(m, 1H, C8), 4.80 (d, J = 5.8 Hz, 1H, H3),  5.01 (d, , J = 8.1 Hz 1H, NH), 5.30 ( d, J = 5.8 
Hz, 1H, H2), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 Hz, 2H, Ar); HRMS calcd for 
C28H41NO9SNa+ [M+Na]+ 590.2394, found 590.2378. 
S-(4-C-Hexyl-D-ribono-1,4-lactone-5-yl)-L-homocysteine (90b). Procedure H. 
Procedure H. Step a. Compound 89b (18 mg, 0.03 mmol) was stirred in TFA (2 mL) at 
0 oC for 1 h then placed in ambient temperature for 3 h. Step b. H2O (0.1 mL) was added 
to the reaction mixture from Step a and stirring was continued for 1 h at ambient 
temperature. Volatiles were evaporated and the residue was coevaporated with 
acetonitrile (0.1 mL) to give 90b (7 mg, 60%): 1H NMR (CDCl3) δ 0.82 (t, J = 6.6 Hz, 
Me, C6a), 1.20-1.28 (m, 12H, C2a-C5a), 1.45-1.50 (m, 2H, C1a), 1.87-2.00 (m, 1H, H7), 
2.05-2.12 (m, 1H, H7'), 2.45-2.55 (m, 2H, H6 & H6'), 2.82 (d, J = 13.6 Hz, 1H, H5), 2.87 
(d, J = 13.6 Hz, 1H, H5'), 4.14 (d, J = 5.4 Hz, 1H, H2), 4.72 (d, J = 5.4 Hz, 1H, H3); 13C 
NMR (CDCl3) δ 15.01 (C6a), 23.20, 23.56, 23.90, 29.20 (C2a-C5a), 32.10 (C1a), 63.25 
(C5), 72.55 (C2), 78.50 (C3), 88.50 (C4), 141.50 (C1). HRMS calcd for C15H27NO6S+ 
[M+H]+ 350.163, found 350.182 and [M+Na]+ 372.145, found 372.161.  
S-(4-C-Octyl-D-ribono-1,4-lactone-5-yl)-L-homocysteine (90c). Treatment of  the 
crude 89c contaminated by the protected homocysteine as described above for 89c (1:5, 
60 mg, 0.02 mmol)  in TFA (2 mL) by Procedure H gave an oily residue that was 
partitioned between water and chloroform. The aqueous layer was evaporated. The 
residue (20 mg) was divided into two portions. Each portion was separately purified on 
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Sep-Pak column (classic C18) as follow. The portion of crude 90c was dissolved in 
water/ACN (2.5 mL, 19:1, v/v) and was injected into the Sepak column. The column was 
eluted with 5 mL of water, a second portion of 5 mL of water and 5mL of ethanol. The 
first water eluent contained mainly Hcy (TLC and 1H NMR) while the ethanol eluent was 
evaporated to give 90c (5 mg, 76%): 1H NMR (CDCl3) δ 0.82 (t, J = 6.6 Hz, Me, C8a), 
1.20-1.28 (m, 12H, C2a-C7a), 1.50-1.60 (m, 2H, C1a), 1.90-2.00 (m, 1H, H7), 2.05-2.12 
(m, 1H, H7'), 2.55-2.65 (m, 2H, H6 & H6'), 2.80 (d, J = 13.8 Hz, 1H, H5), 2.87 (d, J = 
13.9 Hz, 1H, H5'), 4.14 (d, J = 5.4 Hz, 1H, H2), 4.72 (d, J = 5.4 Hz, 1H, H3); 13C NMR 
(CDCl3) δ 15.01 (C8a), 23.00, 23.50, 23.85, 29.00, 30.67, 30.51 (C2a-C7a), 32.07 (C1a), 
60.50 (C6), 61.20 (C7), 62.25 (C5), 71.54 (C2), 77.20 (C3), 84.59 (C4), 141.50 (C1). 
HRMS calcd for C17H31NO6S+ [M+H]+ 378.1945, found 378.1964 and [M+Na]+ 
400.1764, found 400.1783. 
S-(4-C-4-Methoxyphenyl-D-ribono-1,4-lactone-5-yl)-L-homocysteine (90e). 
Treatment of 89e (6.2 mg, 0.01 mmol) with in TFA (1 mL) as described by procedure H 
gave 90e (3 mg, 75%): 1H NMR (CDCl3) δ 1H NMR (CDCl3) δ  3.80 (s, 3H, CH3O), 1.80 
(m, 1H, H7), 1.90 (m, 1H, H7'), 2.50 (m, 2H, H6 and H6'), 2.85 (d, J = 14.8 Hz, 1H, H5), 
3.20 (d, J = 15.1 Hz, 1H, H5'), 4.20 (d, J = 5.8 Hz, 1H, H2),  4.20-4.25 (m, 1H, C8), 4.70 
(d, J = 5.8 Hz, 1H, H3), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 Hz, 2H, Ar); 13C 
NMR (CDCl3) δ 15.01 (C8a), 55.33 (CH3O), 63.20 (C5), 74.40 (C2), 78.20 (C3), 85.40 
(C4), 117.20, 125.81, 127.00, 162.28 (Ar), 143.50 (C1); HRMS calcd for C16H21NO7S+ 
[M+Na]+ 394.0931, found 393.2894. 
2,3-O-Isopropylidene-5-[(tert-butoxycarbonyl)-L-homocysteine tert-butyl ester]-
4-C-hexyl-D-ribofuranose (91b). Procedure I. LiEt3BH (1M/THF, 0.05 mL, 0.05 
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mmol) was added dropwise to a solution of 89b (5 mg, 0.009 mmol) in CH2Cl2 (0.5 mL). 
The mixture was stirred for 30 min at 0 oC (ice-bath) under N2 atmosphere. The reaction 
was quenched with MeOH, the volatiles were then evaporated. The residue was 
partitioned between CH2Cl2 and NaHCO3, washed with brine and dried with anhydrous 
MgSO4. The resulting oil was column chromatographed (80:20, hexane: ethyl acetate) to 
give a 91b mixture of anomers α/β (β major product, 4.5 mg, 90%): 1H NMR (CDCl3) δ 
0.80 (t, J= 6.6 Hz, Me, C8a), 1.2-1.28 (m, 8H, C2a-C5a), 1.35-1.41 (2 x s, 18H), 1.35 (s, 
6H), 1.50-1.60 (m, 2H, C1a), 1.9-2.0 (m, 2H, H7, H7'), 2.48-2.58 (m, 2H, H6, H6'), 2.60 
(d, J = 12.8 Hz, 1H, H5), 2.94 (d, J = 12.6 Hz, 1H, H5'), 4.19-4.21 (m, 1H, H8), 4.44 (d, J 
= 5.9 Hz, 1H, H3), 4.64 (d, J = 5.9 Hz, 1H, H2), 5.19-5.21 (m, 1H, NH), 5.35 (s, 1H, β-
H1). 
2,3-O-Isopropylidene-5-[(tert-butoxycarbonyl)-L-homocysteine tert-butyl ester]-
4-C-4-methoxyphenyl-D-ribofuranose (91e). Treatment of 89e (6 mg, 0.01 mmol) with 
LiEt3BH (25 µL) following procedure I gave 92c (4 mg, 66%): 1H NMR (CDCl3) δ 1.35 
(s, 3H, Me), 1.41 (s, 3H, Me), 1.39 &1.41 (2x s, 18H), 1.80 (m, 1H, H7), 1.90 (m, 1H, 
H7'), 2.50 (m, 2H, H6 and H6'), 3.01 (d, J = 14.8 Hz, 1H, H5), 3.20 (d, J = 15.1 Hz, 1H, 
H5'), 3.60 (d, J = 5.8 Hz, 1H, H3), 3.80 (s, 3H, CH3O), 4.01 (''t'', J = 5.8 Hz, 1H, H2),     
4.20-4.25 (m, 1H, C8), 5.01 (d, , J = 8.1 Hz 1H, NH), 5.60 (s, H1, 1H, major isomer 
99%), 5.80 (d, 1H, minor isomer), 6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 Hz, 2H, 
Ar); HRMS calcd for C28H43NO9S+ [M+Na]+ 592.2551, found 592.2492. 
S-(5-Deoxy-4-C-hexyl-D-ribofuranos-5-yl)-L-homocysteine (92b). Treatment of 
91b (4.5 mg, 0.01 mmol) with in TFA (1 mL) as described by procedure H gave 92b (2 
mg, 75%):1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, Me, C6a), 1.2-1.28 (m, 8H, C2a-C5a), 
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1.50-1.60 (m, 2H, C1a), 1.9-2.0 (m, 2H, H7, H7'), 2.48-2.58 (m, 2H, H6, H6'), 2.60 (d, J 
= 12.8 Hz, 1H, H5), 2.94 (d, J = 12.6 Hz, 1H, H5'), 4.19-4.21 (m, 1H, H8), 4.44 (d, J = 
5.9 Hz, 1H, H3), 4.64 (''t'', J = 5.9 Hz, 1H, H2), 5.19-5.21 (m, 1H, NH), 5.35 (s, 1H, α or 
β-H1); MS (ESI-) m/z 350 (MH-). 
S-(5-Deoxy-4-C-octyl-D-ribofuranos-5-yl)-L-homocysteine (92c). Treatment of 
90c (6 mg, 0.01 mmol) with LiEt3BH (0.03 mL) following procedure I gave 92c (4 mg, 
60%): 1H NMR (CDCl3) δ 0.80 (t, J= 6.6 Hz, Me, C8a), 1.2-1.32 (m, 14H, C2a-C7a), 
1.50-1.60 (m, 2H, C1a), 1.9-2.0 (m, 2H, H7, H7'), 2.48-2.58 (m, 2H, H6, H6'), 2.79 (d, J 
= 12.8 Hz, 1H, H5), 2.90 (d, J = 12.6 Hz, 1H, H5'), 4.19-4.21 (m, 1H, H8), 3.80 (d, J = 
5.9 Hz, 1H, H3), 4.50 (''t'', J = 5.9 Hz, 1H, H2), 5.19-5.21 (m, 1H, NH), 5.80 (s, 0.5H, β-
H1); 5.82 (s, 0.5H, α-H); 13C NMR δ 15.01 (C8a), 23.00, 23.50, 23.85, 29.00, 30.67, 
30.51 (C2a-C7a), 32.07 (C1a), 40.50 (C6), 41.50 (C7), 41.99 (C5), 49.51 (C8), 62.77 
(C3), 72.09 (C2), 87.16 (C4), 99.90 (C1), 174.50 (CO); HRMS calcd for C17H33NO6S+ 
[M+Na]+ 396.2283, found 396.1862. 
S-(5-Deoxy-4-C-4-methoxyphenyl-D-ribofuranos-5-yl)-L-homocysteine (92e). 
Treatment of 91e (4 mg, 0.01 mmol) with in TFA (1 mL) as described by procedure H 
gave 92e (2 mg, 75%): 1H NMR (CDCl3) δ 1.80 (m, 1H, H7), 1.90 (m, 1H, H7'), 2.50 (m, 
2H, H6 and H6'), 3.01 (d, J = 14.8 Hz, 1H, H5), 3.20 (d, J = 15.1 Hz, 1H, H5'), 3.60 (d, J 
= 5.8 Hz, 1H, H3), 3.80 (s, 3H, CH3O), 4.01 (''t'', J = 5.8 Hz, 1H, H2), 4.20-4.25 (m, 1H, 
C8), 5.60 (s, H1, 1H, major isomer 99%),  6.82 (d, J = 8.8 Hz, 2H, Ar), 7.12 (d, J = 9.0 
Hz, 2H, Ar); 13C NMR (CDCl3) δ 15.01 (C8a), 55.33 (CH3O), 63.20 (C5), 64.40 (C2), 
65.20 (C3), 85.40 (C4), 117.20, 125.81, 127.00, 162.28 (Ar), 173.50 (C1). 
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5-O-Acetyl-1-deoxy-2,3-O-isopropylidene-4-thio-D-ribofuranose (94). DMAP (7 
mg, 0.057 mmol) was added to a stirred solution of 93139 (117 mg, 0.62 mmol) in Ac2O 
(6 mL) at ambient temperature. After 2.5 h, MeOH (15 mL) was added and resulting 
mixture was stirred for additional 1 h at 0° C. The volatiles were evaporated to give the 
crude 94 (136 mg, 95%), of sufficient purity to be directly used in next step: 1H NMR δ 
1.34 (s, 3H, Me), 1.54 (s, 3H, Me), 2.10 (s, 3H, Ac), 2.94 (dd, J = 1.2, 13.0 Hz, 1H, H1), 
3.12 (dd, J = 4.7, 13.0 Hz, 1H, H1') 3.49 (ddd, J = 1.0, 5.9, 7.6 Hz, 1H, H4), 4.05 (dd, J = 
8.4, 11.4 Hz, 1H, H5), 4.18 (dd, J = 5.8, 11.4 Hz, 1H, H5'), 4.70 (dd, J = 1.2, 5.6 Hz, 1H, 
H3), 4.94 ('dt', J = 1.3, 5.2 Hz, 1H, H2); 13C NMR δ 20.92 (Ac), 24.66 (CMe2), 26.46 
(CMe2), 37.70 (C1), 52.33 (C4), 64.82 (C5), 83.55 (C2), 85.72 (C3), 111.26 (CMe2), 
170.70 (Ac).  
5-O-Acetyl-1-deoxy-2,3-O-isopropylidene-S-oxo-4-thio-D-ribofuranose 
[95(R/S)S]. A solution of MCPBA (138 mg, 0.56 mmol, ~70% reagent) in CH2Cl2 (3 mL) 
was added dropwise to a solution of 94139 (136 mg, 0.59 mmol) in CH2Cl2 (2 mL) at -78 
°C, under Ar atmosphere. The resulting suspension was stirred for 30 min or until 
disappearance of 94 on TLC (14 h, -78 °C → rt). The reaction mixture was quenched 
with saturated NaHCO3/H2O, and extracted with CH2Cl2. The combined organic layer 
was washed with brine, dried (Na2SO4), and evaporated. The crude product was column 
chromatographed (50% EtOAc/hexane) to give unchanged 94 (7 mg, 5%) followed by 
(EtOAc → 10% MeOH/EtOAc) 95 (133 mg, 91%) as a separable mixture (4:1) of two 
diastereoisomers. Major isomer had: 1H NMR δ 1.33 (s, 3H, Me), 1.49 (s, 3H, Me), 2.10 
(s, 3H, Ac), 3.23 (dd, J = 4.1, 14.4 Hz, 1H, H1), 3.34 (dd, J = 6.4, 14.4 Hz, 1H, H1') 3.36 
('dt', J = 5.6, 8.9 Hz, 1H, H4), 4.49 (dd, J = 8.8, 12.0 Hz, 1H, H5), 4.61 (dd, J = 4.9, 12.0 
102 
 
Hz, 1H, H5'), 4.94 (t, J = 6.1 Hz, 1H, H3), 5.22 (dt, J = 4.2, 6.3 Hz, 1H, H2); 13C NMR δ 
20.80 (Ac), 24.75 (CMe2), 27.29 (CMe2), 56.13 (C1), 58.19 (C5), 63.93 (C4), 79.86 (C2), 
82.75 (C3), 113.47 (CMe2), 170.29 (Ac). Minor isomer had: 1H NMR δ 1.37 (s, 3H, Me), 
1.61 (s, 3H, Me), 2.09 (s, 3H, Ac), 3.22 (dd, J = 6.0, 14.8 Hz, 1H, H1), 3.42 ('td', J = 1.8, 
14.8 Hz, 1H, H1') 3.75-3.79 (m, 1H, H4), 4.35 (dd, J = 5.3, 12.2 Hz, 1H, H5), 4.39 (dd, J 
= 4.5, 12.2 Hz, 1H, H5'), 4.86 (dd, J = 2.7, 5.9 Hz, 1H, H3), 5.14 (dt, J = 2.2, 6.0 Hz, 1H, 
H2); 13C NMR δ 20.69 (Ac), 24.48 (CMe2), 26.82 (CMe2), 57.25 (C1), 60.93 (C5), 71.40 
(C4), 82.87 (C2), 84.45 (C3), 112.91 (CMe2), 170.00 (Ac); MS (ESI) m/z 249 (100, 
[MH]+). 
5-O-Acetyl-1-deoxy-1-fluoro-2,3-O-isopropylidene-4-thio-α/β-D-ribofuranose 
(96), and 5-O-Acetyl-2,3-O-isopropylidene-4-thio-β-D-ribofuranose (99). Procedure 
J. Deoxo-fluor (125 mg, 0.25 mL of 50% solution in THF, 0.57 mmol) was added to a 
stirred solution of sulfoxide 95 (15.5 mg, 0.11 mmol) in CH2Cl2 (0.5 mL) containing 
SbCl3 (30 mg, 0.13 mmol) under Ar atmosphere at ambient temperature. Reaction 
mixture was heated at 55 ºC for 3 h, and was quenched with saturated NaHCO3/H2O. The 
resulting mixture was extracted with CH2Cl2 and the combined organic layer was washed 
with brine, dried (Na2SO4), and evaporated. The crude product was column 
chromatographed (20 → 25% EtOAc/hexane) to give 96 (9 mg, 58%) as colorless oil of 
major β anomer. 1H NMR δ 1.33 (s, 3H, Me), 1.48 (s, 3H, Me), 2.10 (s, 3H, Ac), 3.67 
(ddd, J = 2.5, 5.3, 10.1 Hz, 1H, H4), 4.06 ('t', J = 10.8 Hz, 1H, H5), 4.27 (dd, J = 5.3, 
11.6 Hz, 1H, H5'), 4.94 (d, J = 5.4 Hz, 1H, H3), 5.03 (dd, J = 5.4, 9.5 Hz, 1H, H2), 5.97 
(d, J = 54.0 Hz, 1H, H1); 13C NMR δ 20.81 (Ac), 24.57 (CMe2), 26.33 (CMe2), 54.86 (d, 
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J = 1.8 Hz, C4), 65.82 (C5), 84.81 (C3), 89.15 (d, J = 38.6 Hz, C2), 106.60 (d, J = 218.3 
Hz, C1), 111.33 (CMe2), 170.47 (Ac); 19F NMR δ -140.85 (ddd, J = 2.3, 9.5, 54.0 Hz).  
A further elution (25% EtOAc/hexane) afforded an analytical sample of the minor α 
anomer of 96 (1.1 mg, 7%): 1H NMR δ 1.38 (s, 3, Me), 1.56 (s, 3, Me), 2.10 (s, 3, Ac), 
3.98-4.03 (m, 1H, H4), 4.19 (dd, J = 6.3, 11.6 Hz, 1H, H5), 4.34 (dd, J = 6.2, 11.5 Hz, 
1H, H5'), 4.67 (dd, J = 3.5, 6.7 Hz, 1H, H3), 4.83 (ddd, J = 4.4, 6.7, 15.2 Hz, 1H, H2), 
5.81 (dd, J = 4.4, 56.7 Hz, 1H, H1); 13C NMR δ 20.72 (Ac), 25.82 (d, J = 1.4 Hz, CMe2), 
25.94 (d, J = 2.3 Hz, CMe2), 48.96 (C4), 64.42 (d, J = 2.1 Hz, C5), 83.21 (C3), 85.06 (d, 
J = 19.8 Hz, C2), 98.02 (d, J = 231.5 Hz, C1), 115.27 (CMe2), 170.49 (Ac); 19F NMR δ -
157.24 (dd, J = 15.2, 56.7 Hz); MS (ESI) m/z 250 (100, M+). 
Additional elution (40% EtOAc/hexane) resulted in the separation of the 
thiohemiacetal 99 (β–anomer; 2.6 mg, 17%). 1H NMR δ 1.34 (s, 3H, Me), 1.52 (s, 3H, 
Me), 2.13 (s, 3H, Ac), 2.50 (br. s, OH), 3.63-3.68 (m, 1H, H4), 4.17 (dd, J = 8.9, 11.4 Hz, 
1H, H5), 4.41 (dd, J = 5.8, 11.4 Hz, 1H, H5'), 4.87 (d, J = 5.4 Hz, 1H, H3), 4.92 (d, J = 
5.4 Hz, 1H, H2), 5.37 (br. s, 1H, H1); 13C NMR δ 20.90 (Ac), 24.56 (CMe2), 26.44 
(CMe2), 54.83 (C4), 66.53 (C5), 85.78 (C3), 86.98 (C1), 90.47 (C2), 110.82 (CMe2), 
170.57 (Ac).  
Procedure K: Sulfide 94 (27.5 mg, 0.12 mmol) was treated with Deoxo-fluor (127 
mg, 0.26 mL, 50% soln in THF, 0.59 mmol) and SbCl3 (30 mg, 0.13 mmol) as described 
above (Procedure J, 4 h). The crude product (spectrally identical to the crude sample 
obtained by Procedure J) was column chromatographed (20 → 25% EtOAc/hexane) to 
give major β anomer of 96 (14.5 mg, 49%) as colorless oil. 
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1-Deoxy-1-fluoro-2,3-O-isopropylidene-4-thio-β-D-ribofuranose (97). Compound 
96 (β–anomer; 45 mg, 0.18 mmol) was dissolved in saturated methanolic ammonia 
solution (4 mL) and the resulting mixture was stirred for 15 h at ambient temperature. 
The volatiles were evaporated to give crude product 97 (37 mg, 99%) as a light yellow oil 
of sufficient purity to be used for next step. 1H NMR δ 1.32 (s, 3H, Me), 1.49 (s, 3H, 
Me), 2.02 (s, 1H, OH), 3.64-3.79 (m, 3H, H4, H5, H5'), 4.96 (d, J = 5.4 Hz, 1H, H3), 
5.01 (dd, J = 5.4, 10.2 Hz, 1H, H2), 5.99 (d, J = 55.7 Hz, 1H, H1); 13C NMR δ 24.43 
(CMe2), 26.37 (CMe2), 59.38 (d, J = 1.9 Hz, C4), 64.97 (d, J = 1.4 Hz, C5), 85.22 (C3), 
89.64 (d, J = 36.9 Hz, C2), 107.16 (d, J = 216.8 Hz, C1), 110.99 (CMe2); 19F NMR δ -
137.16 (dd, J = 10.3, 55.8 Hz).   
1-Deoxy-1-fluoro-2,3-O-isopropylidene-5-O-methanesulfonyl-4-thio-β-D-
ribofuranose (98). Compound 97 (37 mg, 0.18 mmol) was treated with MsCl (0.16 mL, 
237 mg, 3.31 mmol) in the presence of Et3N (0.6 mL, 437 mg, 4.33 mmol) by Procedure 
A (18 h, 0 ºC → rt). The crude product (104 mg) was column chromatographed (20% → 
40 % EtOAc/hexane) to give 98 (31 mg, 61%): 1H NMR δ 1.33 (s, 3H, Me), 1.48 (s, 3H, 
Me), 3.07 (s, 3H, Ms), 3.76 (ddd, J = 2.2, 5.3, 10.2 Hz, 1H, H4), 4.17 ('t', J = 10.5 Hz, 
1H, H5), 4.34 (dd, J = 5.3, 10.7 Hz, 1H, H5'), 5.01-5.03 (m, 1H, H3), 5.03-5.07 (m, 1H, 
H2), 5.99 (d, J = 53.6 Hz, 1H, H1); 13C NMR δ 24.49 (CMe2), 26.24 (CMe2), 37.73 (Ms), 
54.80 (C4), 69.85 (C5), 84.16 (C3), 88.84 (d, J = 38.6 Hz, C2), 106.58 (d, J = 218.0 Hz, 
C1), 111.58 (CMe2); 19F NMR δ -140.85 (ddd, J = 1.9, 8.7, 53.6 Hz).  
S-(1,5-Dideoxy-1-fluoro-2,3-O-isopropylidene-4-thio-β-D-ribofuranos-5-yl)-N-
(tert-butoxycarbonyl)-L-homocysteine tert-butyl ester (100), and S-(5-Deoxy-2,3-O-
105 
 
isopropylidene-4-thio-β-D-ribofuranos-5-yl)-N-(tert-butoxycarbonyl)-L-
homocysteine tert-butyl ester (101). Compound 98 (31 mg, 0.11 mmol) was treated with 
lithium homocysteinate (91 mg, 0.31 mmol) by Procedure G (3h). The crude product was 
column chromatographed (15 → 20% EtOAc/hexane) to give 100 (13 mg, 25%) as a 
colorless oil: 1H NMR δ 1.34 (s, Me, 3H), 1.47 (s, 9H), 1.49 (s, 12H), 1.85-1.95 (m, 1H, 
H8), 2.04-2.16 (m, 1H, H8'), 2.60-2.66 (m, 2H, H7, H7'), 2.71 (dd, J = 11.1, 13.9 Hz, 1H, 
H5), 2.87 (dd, J = 5.7, 13.9 Hz, 1H, H5'), 3.55 (ddd, J = 2.3, 5.4, 10.9 Hz, 1H, H4), 4.26-
4-34 (m, 1H, H9), 5.04 (d, J = 0.8 Hz, 1H, H3), 5.06 (d, 1, J = 2.9 Hz, 1H, H2), 5.11 (br. 
d, J = 6.9 Hz, 1H, NH), 6.00 (d, J = 53.7 Hz, 1H, H1); 13C NMR δ 24.59 (CMe2), 26.31 
(CMe2), 28.02 (t-Bu), 28.33 (C7, t-Bu), 33.11 (C8), 38.14 (C5), 53.32 (C9), 56.43 (d, J = 
1.8 Hz, C4), 79.87 (t-Bu), 82.31 (t-Bu), 85.98 (C3), 88.86 (d, J = 39.2 Hz, C2), 107.09 (d, 
J = 216.9 Hz, C1), 111.21 (CMe2), 155.35 (CO), 171.20 (C10); 19F NMR δ -140.87 (dd, J 
= 3.8, 53.8 Hz); MS (ESI) m/z 462 (100, [M-19]+). HRMS (AP-ESI) m/z calcd for 
C21H36FNNaO6S2 [M+Na]+ 504.1860; found 504.1847. 
Further elution (25 → 30% EtOAc/hexane) afforded 101 (14 mg, 27%) as a colorless 
oil of single β anomer: 1H NMR δ 1.33 (s, 3H), 1.47 (s, 9H), 1.49 (s, 9H), 1.51 (s, 3H), 
1.89-2.00 (m, 1H, H8), 2.07 (tdd, J = 5.8, 9.6, 13.7 Hz, 1H, H8'), 2.59-2.67 (m, 1H, H7), 
2.68-2.77 (m, 1H, H7'), 2.85-2.94 (br., OH), 2.89 (dd, J = 8.7, 13.5 Hz, 1H, H5), 2.97 
(dd, J = 6.8, 13.6 Hz, 1H, H5'), 3.56 (t, J = 7.9 Hz, 1H, H4), 4.27-4-35 (m, 1H, H9), 4.87 
(d, J = 5.4 Hz, 1H, H2), 4.95 (d, 1, J = 5.4 Hz, 1H, H3), 5.18 (br. d, J = 6.9 Hz, 1H, NH), 
5.41 (s, 1H, H1); 13C NMR δ 24.61 (CMe2), 26.48 (CMe2), 28.03 (t-Bu), 28.26 (C7), 
28.34 (t-Bu) 33.05 (C8), 38.34 (C5), 53.31 (C9), 56.92 (C4), 80.01 (t-Bu), 82.39 (t-Bu), 
87.37 (C1), 87.65 (C3), 90.22 (C2), 110.67 (CMe2), 155.39 (CO), 171.21 (C10); MS 
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(ESI) m/z 462 (100, [M-17]+) 480 (30, [MH]+); HRMS (ESI) m/z calcd for 
C21H37NNaO7S2 [M+Na]+ 502.1909; found 502.1884. 
S-(5-Deoxy-4-thio-D-ribofuranos-5-yl)-L-homocysteine (39). Method A. 
Compound 100 (13 mg, 0.027 mmol) was treated with aqueous TFA by Procedure H (4 
h) to give colorless oil of 39 (7 mg, 91%) as a mixture of anomers whose ratio changed 
when stored as D2O solution (1:1 → 1:4, α:β). Major β-isomer had: 1H NMR (D2O) δ 
2.25-2.45 (m, 2H, H8, H8'), 2.78 (dd, J = 8.7, 13.4 Hz, 1H, H5), 2.87 (t, J = 7.3 Hz, 2H, 
H7, H7'), 3.20 (dd, J = 4.6, 13.4 Hz, 1H, H5'), 3.54 (ddd, J = 4.6, 7.8, 9.0 Hz, 1H, H4), 
4.16-4.21 (m, 3H, H2, H3, H9), 5.16 (d, J = 1.6 Hz, 1H, H1); 13C NMR (D2O) δ 29.20 
(C8), 32.32 (C7), 35.68 (C5), 48.81 (C4), 51.69 (C9), 76.75, 79.64 (C2, C3), 81.08 (C1), 
171.75 (C10). Minor α-isomer had: 1H NMR (D2O) δ 2.25-2.45 (m, 2, H8, H8'), 2.67 (dd, 
J = 8.7, 13.5 Hz, 1H, H5), 2.87 (t, J = 7.3 Hz, 2H, H7, H7'), 3.03 (dd, J = 5.5, 13.4 Hz, 
1H, H5'), 3.77 (dt, J = 5.6, 8.7, Hz, 1H, H4), 4.10 (dd, J = 3.7, 5.7 Hz, 1H, H3), 4.16-4.21 
(m, 1H, H9), 4.24 (t, J = 4.0 Hz, 1H, H2), 5.45 (d, J = 4.3 Hz, 1H, H1); MS (ESI) m/z 
284 (100, [MH]+). HRMS (AP-ESI) m/z calculated for C9H16NO5S2 [M-H]- 282.0475; 
found 282.0484. 
Method B. Compound 101 (6 mg, 0.012 mmol) was treated with aqueous TFA by 
Procedure H (4 h) to give 39 (3 mg, 85%) as a colorless oil with spectral data identical to 
the sample of 39 obtained from Method A. 
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4.3. Biological Assays 
4.3.1 Anti-QS assay for 4-[thia]-SRH 
4.4.1.1. β-galactosidase assay 
An overnight culture of E. coli DH5α harboring the plasmids pSC11, which contains 
a PlasI-lacZ translational fusion148 and pJN105L, which contains a PBAD-lasR  expression 
plasmid149 grown in LB media (10 g tryptone, 5 g yeast extract, 5 g sodium chloride per 
liter) supplemented with ampillicin (100 μg/ ml) and gentamycin (15 μg/ ml), was diluted 
to an OD600 of 0.150. At this time, arabinose (0.2 % w/v), N-3-
(oxododecanoyl)homoserine lactone (3-oxo-C12-AHL; 2 μM), and either the compound 
under analysis, water extract from Conocarpus erectus or Callistemon viminalis150 or 
solvent (water or DMSO), were added to the culture (1.5 mL). A negative control 
containing only solvent and arabinose (0.2% w/v) was also assayed.  The cultures were 
incubated with shaking for three hours at 37 °C.  
The conditions for the rhl biomonitor E. coli DH5α harboring pECP61.5 plasmid151, 
were essentially same except that the LB medium was only supplemented with ampillicin 
(100 μg/ ml), the overnight culture was diluted to an OD600 of 0.150, induced with 1 
mM isopropyl β-D-thiogalactoside (IPTG), 2 μM C4-AHL and the compounds or the 
controls added when the OD600 reached 1.0. After incubation at 37 °C for 4 hours with 
shaking, β -galactosidase activity was assayed as described previously.152 Assays were 
repeated at least twice. For each biological replicate, experimental triplicates were 
performed and the average percent activity calculated by dividing the average Miller 
units from the samples containing compound or extract by the average Miller units from 
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the sample containing solvent and multiplying by 100. Significance of inhibition was 
determined using a paired two-tailed Student t-test. 
4.3.1.2. Growth and luminescence measurement drop assay 
Growth and luminescence measurement drop assays were conducted by Professor 
Makemson at FIU. The V. harveyi strain B392 (MAV) (or strain BB170 (AI-1-, AI-2+) or 
strain BB152 (AI-1-, AI-2+), was grown in AB medium (75% artificial sea water, 0.3% 
glycerol, 0.2% casamino acids, 0.02 % glycerol-phosphate, 25  mM HEPES buffer) at a 
pH 7.5153 Growth was measured in a Spectronic 20 as OD660nm and luminescence was 
measured in a calibrated photometer and recorded in light units (1 LU = 1.08 x 108 
q/s/mL). An overnight culture of V. harveyi was added to 45 mL of AB medium to an 
OD660nm of ~0.03, When the culture was rapidly growing (OD660nm ~0.05 to 0.07), the 
culture was split (2.5 mL/ 13x100mm culture tubes) and small amounts (2.5 µL and 10 
µL) of each compound were added to each tube. The compound, dissolved in water or 
DMSO served as a control. Each measurement was obtained from a single trial and 
luminescence without inhibitor was considered 100%. 
4.3.2. Anti-QS assay for 4-C-alkyl/aryl-SRH 
The 4-C-alkyl/aryl-[SRH] analogues and the 4-[thia]-SRH analogues synthesized in 
this dissertation will be evaluated for the inhibition of  LuxS enzyme in the laboratoty of 
Professor Dehua Pei at the University of Ohio.  
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5. CONCLUSION 
I have developed different strategies for the synthesis of the three novel classes of S-
ribosylhomocysteine (SRH) analogues which were designed as potential inhibitors of the 
S-ribosylhomocyteinase enzyme (LuxS). The first class I attempted to prepare was 2-
halo-SRH analogues. The 2-deoxy-2-fluoro pentafuranosyl precursors were prepared 
from the D-allose in a multistep procedure, which involved dehomologation and 
intramolecular rearrangement of the 3-deoxy-3-fluoroglucose to 2-deoxy-2-
fluoroarabinose.  The 2-bromo-2-deoxy pentafuranosyl precursors were prepared by 
direct bromination of the suitably protected 2-deoxyribono-1,4-lactone with N-
bromosuccinimide in the presence of trimethylsilyl triflate resulting in the formation of 2-
bromo-2-deoxyribono-1,4-lactones as a mixture of arabino/ribo epimers in 2:1 ratio. The 
5-hydroxyl group in 2-bromo-2-deoxyarabinono-1,4-lactones was activated by the 
conversion to the methylsulfonate ester. However attempts of the displacement of the 
mesylate group with the suitably protected homocysteinate anion led to the substitution of 
the secondary bromine at the α-position to the carbonyl group in ribonolactones rather 
than the replacement of the primary mesylate group. Model reaction with propanethiol 
confirmed that the displacement of the bromide from C2 takes precedence over the 
substitution of the mesylate from the C5 leading to the formation 2-S-propyl substituted 
2-thioribonolactone. 
The second class was the 4-C-alkyl/aryl-S-ribosylhomocysteine analogues synthesis 
of which was accomplished from D-ribose. The preparation of the ribono-1,4-lactone 
analogues of 4-C-substituted SRH involved the following critical steps: (i) conversion of 
the D-ribose to the ribitol-4-ulose; (ii) diastereoselective addition of various alkyl or aryl 
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or vinyl Grignard reagents to 4-ketone intermediate; (iii) oxidation of the primary 
hydroxyl group at C1 followed by the intramolecular ring closure to the corresponding 4-
C-alkyl/aryl-substituted ribono-1,4-lactones; (iv) displacement of the activated 5-
hydroxyl group with the protected homocysteinate. Treatment of these 4-C-alkyl/aryl-
substituted SRH analogues with lithium triethylborohydride effected reduction of the 
ribonolactone to the ribose (hemiacetal) and subsequent global deprotection with 
trifluoroacetic acid provided 4-C-alkyl/aryl-SRHs. 
The third class was the 4-[thia]-SRH analogues synthesis which started from the 
1-deoxy-4-thioribose which was in turns prepared from D-ribose. Treatment of the 1-
deoxy-4-thioribose thioether or the corresponding sulfoxides with DAST/SbCl3 
combination resulted in the fluoro-Pummerer rearrangement to give the corresponding 
thioribosyl fluorides in high yields. These α-fluoro thioethers were sensitive to acidic 
conditions and underwent hydrolysis to the corresponding thiohemiacetals. However, the 
α-fluoro thioethers (thioribosyl fluorides) were relatively stable to basic conditions, in 
parallel with acetals. Thus, ribosyl fluorides were mesylated at primary 5-hydroxyl and 
subsequent coupling with the protected homocysteinate anion afforded the relatively 
stable 4-[thia]-SRH fluoride. Treatment of the latter with aqueous TFA effected 
hydrolysis of the fluoride as well as the global removal of the N-Boc, acetonide, and t-
butyl ester protection groups in a single step to give 4-[thia]-SRH derivative as a mixture 
of α:β anomers. 
The 4-[thia]-SRH analogues were evaluated for their effect on P. aeruginosa QS. 
All the tested 4-[thia] derivatives showed a general concentration-dependent (50-200 
µG/mL) inhibition of las QS pathways, while none of them affected rhl gene. The most 
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active was 1-deoxy-4-[thia]-SRH analogue with the sufur atom in the ring oxidized to the 
sulfoxide decreasing las gene activity to approximately 35%. In addition 4-[thia]-SRH 
analogues were tested for their effect on QS, bioluminescence and growth of the V. 
harveyi.  They did not display any significant effects. The interaction of the prepared 
SRH analogues with LuxS and their effect in other QS sytems are currently being 
evaluated in the collaboration with other research groups. 
Future research direction will depend on the results generated from the interaction 
of the synthesized analogues of SRH with LuxS enzyme. It might, however, involve the 
synthesis of different thio-DPD and aza-DPD analogues and study their borate 
complexation to help us to understand better the mechanism of action and the binding 
properties. The bulky 4-C-alkyl/aryl SRH should be used to study dimer interface of 
LuxS and the disruption of the dimerization processes. The use of the fluorescence 
proximity assay, which is a technique used to test the inhibition of a dimeric protein in 
presence of an inhibitor by measuring the change in fluorescence upon monomer 
separation, can be used in future studies. 
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